<SEC-DOCUMENT>0001140361-26-010656.txt : 20260323
<SEC-HEADER>0001140361-26-010656.hdr.sgml : 20260323
<ACCEPTANCE-DATETIME>20260323084409
ACCESSION NUMBER:		0001140361-26-010656
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260323
DATE AS OF CHANGE:		20260323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		26780015

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7TH FLOOR, 50 BROADWAY
		CITY:			LONDON
		NON US STATE TERRITORY:  	UNITED KINGDOM
		PROVINCE COUNTRY:   	X0
		ZIP:			SW1H 0DB
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7TH FLOOR, 50 BROADWAY
		CITY:			LONDON
		NON US STATE TERRITORY:  	UNITED KINGDOM
		PROVINCE COUNTRY:   	X0
		ZIP:			SW1H 0DB
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>ef20068452_8ka.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:roiv="http://roivant.com/20260303" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_173987dffc66412481442c35adce3f05" contextRef="c20260303to20260303" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_2733d47eee5b40e6a5d26e9ec617c72a" contextRef="c20260303to20260303">0001635088</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="roiv-20260303.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20260303to20260303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-03</xbrli:startDate><xbrli:endDate>2026-03-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_03b10c1b292e4aaf817a01cc3f244a02" contextRef="c20260303to20260303">8-K/A</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Amendment No. 1)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Securities Exchange Act of 1934</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c8c6affcacf0487eb5bae78d3d2a174a" contextRef="c20260303to20260303" format="ixt:date-monthname-day-year-en">March 3, 2026</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_13281207eecf4bb4be3e33b81dbeccc3" contextRef="c20260303to20260303">Roivant Sciences Ltd.</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_112a74d77838425eaf6c5e05f757e37e" contextRef="c20260303to20260303" format="ixt-sec:edgarprovcountryen">Bermuda</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_dfe7f17ac7e04eee8dcf2a65e9b5fa1c" contextRef="c20260303to20260303">001-40782</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_03969f308e00462e8da781db3a32ddf2" contextRef="c20260303to20260303">98-1173944</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_8c77e1c9cea84d51a8d5a0bafda0157a" contextRef="c20260303to20260303">7th Floor</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_2d608e5d97674b98a54ff84f23f2f6fb" contextRef="c20260303to20260303">50 Broadway</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_1466c9deaad6444a89bebbc1c845db43" contextRef="c20260303to20260303">London</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_574ebeb9cddd44abbd96d2cb37f1371d" contextRef="c20260303to20260303">SW1H 0DB</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_bfd51f3709874c558d3b1613721b6fd0" contextRef="c20260303to20260303" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1 Pennsylvania Plaza</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Floor 54</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">New York, NY 10119</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">United States<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Viaduktstrasse 8</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4051 Basel</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Switzerland<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Address of principal executive offices, and Zip Code)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">+44 <ix:nonNumeric name="dei:CityAreaCode" id="Fact_703642680bfb416bb00aa0c4749e8594" contextRef="c20260303to20260303">207</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_5a2cfd84016b4311b81f1441825eec76" contextRef="c20260303to20260303">400-3347</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s Telephone Number, Including Area Code</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
        (<span style="font-style: italic;">see </span>General Instruction A.2. below):</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_241596e971354a9498aad548257e68be" contextRef="c20260303to20260303" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_f5200c264f454868a9163d759958a4ad" contextRef="c20260303to20260303" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_9ed51f7afc48491888811bf947ffb594" contextRef="c20260303to20260303" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_36be14c54212463c9ec777bfc9347ca2" contextRef="c20260303to20260303" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br/>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; margin-right: 0.1pt; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 19.86%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; margin-right: 0.2pt; margin-left: 0.05pt; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 37.52%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; margin-right: 0.05pt; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; margin-right: 0.1pt; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_6613dfebb7bc4f97a63ff9b02429b499" contextRef="c20260303to20260303">Common Shares, $0.0000000341740141 per share</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 19.86%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; margin-right: 0.2pt; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_6644577ba67f4126a2b617b5b2df97c6" contextRef="c20260303to20260303">ROIV</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 37.52%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; margin-right: 0.05pt; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_14fe63333af0418f8e026a013374c4ef" contextRef="c20260303to20260303" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2
        of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#160;Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_dfef9264f98540829d0d8fe301690404" contextRef="c20260303to20260303" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    </div>

    <div><br/></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Addresses of wholly-owned subsidiaries of the Registrant.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Explanatory Note</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This Amendment No. 1 on Form 8-K/A (this &#8220;Amendment&#8221;) amends the Current Report on Form 8-K of Roivant Sciences Ltd. (the &#8220;Company&#8221; or &#8220;Roivant&#8221;) filed with the U.S.
      Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 3, 2026 (the &#8220;Original 8-K&#8221;). The Original 8-K disclosed the entry into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;), dated March 3, 2026, by and among Genevant Sciences GmbH
      (&#8220;Genevant&#8221;), a subsidiary of Roivant, Arbutus Biopharma Corp. (&#8220;Arbutus&#8221; and, together with Genevant, &#8220;Genevant/Arbutus&#8221;), and, solely for certain purposes, Genevant Sciences Ltd. (&#8220;GSL&#8221;), and Moderna, Inc. and ModernaTx, Inc. (together, &#8220;Moderna&#8221;).</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The sole purpose of this Amendment is to file the Settlement Agreement as Exhibit 10.1 hereto in accordance with the disclosure in Item 1.01 of the Original 8-K, which
      indicated that a copy of the Settlement Agreement would be filed as an exhibit to a subsequent filing with the SEC.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Except as set forth herein, no other changes have been made to the Original 8-K, and this Amendment does not modify or update any other disclosures set forth in the
      Original 8-K. This Amendment should be read in conjunction with the Original 8-K.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="font-weight: bold;">Entry into a Material Definitive Agreement</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The disclosure set forth in Item 1.01 of the Original 8-K is hereby incorporated by reference. As described in the Original 8-K, on March 3, 2026, Genevant, Arbutus and,
      solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of
      Genevant/Arbutus&#8217; lipid nanoparticle delivery technology in its vaccines.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Settlement Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the
      Settlement Agreement, a copy of which is filed as Exhibit 10.1 to this Amendment and is incorporated herein by reference.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="font-weight: bold;">Financial Statements and Exhibits</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

    <div style="text-align: left; margin-left: 16.45pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exhibit No.</span></td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Description

                of Exhibit</span></span></td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;"><a href="ef20068452_ex10-1.htm">10.1*&#x5E;</a></div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">Settlement Agreement, dated March 3, 2026.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">104</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">Cover Page Interactive Data File (embedded with Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">* Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because those portions are both not material and are the type that
      the Company treats as private or confidential.</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#x5E; Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
      authorized.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-weight: bold;">ROIVANT SCIENCES LTD.</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3"><br/>
          </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left;">By:</div>
          </td>

    <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"> /s/ Keyur Parekh</td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;"><br/>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
            <div style="text-align: left;">Name: Keyur Parekh</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
            <div style="text-align: left;">Title: Authorized Signatory</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
            <div style="text-align: left;">Dated: March 23, 2026</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ef20068452_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div class="BRPFPageHeader" style="width: 100%;"></div>
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
  <div style="text-align: left; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 10.1</font><font style="font-size: 10pt;"><br>
    </font></div>
  <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>SETTLEMENT AGREEMENT</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">This Settlement Agreement (&#8220;Agreement&#8221;) is entered into as of March 3, 2026 (the &#8220;Effective Date&#8221;) by and between, on the one hand, Genevant Sciences
      GmbH ( &#8220;Genevant&#8221;), a limited liability company organized under the laws of Switzerland having a principal place of business at Viaduktstrasse 8, 4051 Basel, Switzerland, and Arbutus Biopharma Corp. (&#8220;Arbutus&#8221;), a British Columbia corporation having
      an address at 700 West Georgia St., 25th Floor, Vancouver, British Columbia V7Y1B3 Canada, and, on the other hand, Moderna, Inc., a Delaware corporation having its principal place of business at 325 Binney Street, Cambridge, Massachusetts 02142, and
      ModernaTX, Inc., a Delaware corporation having its principal place of business at 325 Binney Street, Cambridge, Massachusetts 02142. For purposes of this Agreement, Genevant and Arbutus shall be referred to collectively as &#8220;Genevant/Arbutus,&#8221; and
      Moderna, Inc. and ModernaTX, Inc. shall be referred to collectively as &#8220;Moderna.&#8221; The aforementioned entities are individually referred to herein as a &#8220;Party&#8221; and collectively as the &#8220;Parties.&#8221; In addition, Genevant Sciences Ltd. (&#8220;Genevant Parent&#8221;)
      is also a signatory and a &#8220;Party&#8221; to this Agreement, but solely for purposes of [***].</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS Arbutus owns, and Genevant licenses, U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 (collectively, the
      &#8220;Asserted US Patents&#8221;);</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS Genevant/Arbutus have sued Moderna in Civil Action No. 1-22-cv-00252-JDW in the U.S. District Court for the District of Delaware (the &#8220;US
      Litigation&#8221;), in which Genevant/Arbutus have alleged infringement of the Asserted US Patents relating to Moderna&#8217;s SPIKEVAX (COVID-19 vaccine, mRNA) and Moderna has asserted certain affirmative defenses and counterclaims;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS Moderna has alleged that, pursuant to 28 U.S.C. &#167; 1498, it is not the proper party to compensate Genevant/Arbutus for any patent infringement in
      connection with sales to the United States Government under the C-100 Contract (as defined below);</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS the Court denied-in-part and granted-in-part Moderna&#8217;s motion for summary judgment and granted-in-part and denied-in-part Genevant/Arbutus&#8217;
      motion for summary judgment concerning the application of &#167; 1498(a) to doses supplied under the C-100 Contract in the Court&#8217;s opinion and order dated February 2, 2026 [D.I. 697 and 698];</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS Genevant Parent, the indirect parent of Genevant, is not a claimant in the US Litigation or the Ex-US Litigation, is not a direct beneficiary of
      any potential resolution of the US Litigation or the Ex-US Litigation, is not an intended direct beneficiary of the cash Payments to Genevant/Arbutus contemplated by this Agreement, and does not directly own or license the Genevant/Arbutus Patent
      Rights or the EPO Patent Rights, but is a Party to this Agreement solely for purposes of the Genevant Parent Provisions;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
      </font></div>
  </div>
  <div style="font-family: 'Times New Roman'; font-size: 10pt;">
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)
                  IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
              </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: center;">1<br>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div class="BRPFPageHeader" style="width: 100%;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
      </div>
    </div>
    <div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS the Parties wish to stipulate to the entry of judgment in the US Litigation while preserving Moderna&#8217;s ability to appeal the Court&#8217;s ruling
          with respect to the &#167; 1498 Disputed Matter, and this Agreement sets forth the terms and conditions regarding same;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS the Parties or their Affiliates are also involved in various patent litigation proceedings outside the United States; and</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">WHEREAS, to avoid the time and expense of litigation, in recognition of the inherent risks and costs of litigation and appeal, the Parties wish to
          resolve and settle the US Litigation and the Ex-US Litigation (as defined below) on the terms and conditions set forth below.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">NOW THEREFORE, in consideration of all the above premises and terms and conditions of this Agreement, and other good and valuable
          consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zda399437092042459e0c51ef19f265e2">

            <tr>
              <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; width: 18pt;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>Definitions</u></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The following terms used in this Agreement shall have the meanings assigned to them in this Section 1 and shall include the singular as well as the
          plural.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc60f0eaa94f54234881557fd883604e0">

            <tr>
              <td style="width: 18pt;">&#160;</td>
              <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 27pt;">1.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;&#167; 1498 Disputed Matter&#8221; means whether 28 U.S.C. &#167;1498 bars Genevant/Arbutus&#8217; direct infringement claims and Genevant/Arbutus&#8217; indirect infringement claims against Moderna for the Disputed Doses.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92ef9ea6dfca436ca485521084d69555">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;&#167; 1498 Judgment&#8221; means the judgment reflected in Paragraph 3a of the proposed Consent Judgment and Order for the US Litigation contained in Exhibit 2.3.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z97972ba1c6914c2ebe8a66dcca9cf991">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.3</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Affiliate&#8221; means, with respect to a Person, any Person that, now or hereafter, is directly or indirectly controlled by, under common control with or that controls such Person; provided that,
                  notwithstanding the foregoing, solely as used in Sections 1.8, 1.11, 4.1, 4.3, and 4.4 with respect to (A) each of Genevant and Genevant Parent, &#8220;Affiliate&#8221; means solely Genevant Parent and its direct and indirect wholly owned
                  subsidiaries and (B) Arbutus, &#8220;Affiliate&#8221; means solely Arbutus Biopharma Corporation and its direct and indirect wholly owned subsidiaries. For purposes of this definition and the definition of &#8220;Change of Control,&#8221; &#8220;control&#8221; or
                  &#8220;controlled&#8221; means direct or indirect ownership or control of at least fifty percent (50%), including ownership by trusts with substantially the same beneficial interests, of the voting rights of such Person, or the power to direct the
                  management of such Person.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z95611e56c1654fe09eca5c914c8c2fef">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.4</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Business Day&#8221; means a day other than Saturday, Sunday, or a United States federal or Delaware state holiday.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z15849a6f90a449c1bde922c44205c773">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.5</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;C-100 Contract&#8221; means Contract No. W911QY20C0100, including modifications in effect as of the Effective Date that were disclosed to Genevant/Arbutus and Genevant/Arbutus counsel, including by
                  production in the US Litigation, prior to the Effective Date.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">2</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8041b5250ce648b1870a7cfb8839e661">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.6</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Change of Control&#8221; of Moderna means any transaction or series of related transactions in which (a) a Third Party acquires, directly or indirectly, control of Moderna, Inc. or ModernaTX, Inc.
                  (each, a &#8220;Moderna Party&#8221;), (b) a Moderna Party merges with or into a Third Party and the holders of voting rights of such Moderna Party immediately prior to such transaction do not hold more than fifty percent (50%) of the voting rights
                  of the surviving entity immediately after such transaction, or (c) a Moderna Party sells all or substantially all of its assets to a Third Party.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za4fae7c0f5c243409b720544b2e94882">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.7</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Disputed Doses&#8221; means 493,757,200 doses that were sold to the United States Government under the C-100 Contract and which were characterized by the district court in the US Litigation (D.I. 698)
                  as &#8220;vaccines that did not go directly to United States Government employees.&#8221;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za3e857fe5270464ea8b943a3a856cbde">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.8</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;EPO Patent Rights&#8221; means:</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
          </font></div>
        <div style="text-align: left; margin-left: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">European Patent Nos.
              2279254 and 4241767, and any European patent applications from which they derive;</font></font></div>
        <div style="text-align: left; margin-left: 54pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
            </font></font></div>
        <div style="text-align: left; margin-left: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">any European patents granted on the
              applications identified in clause (a), whether as European bundle patents under the EPC or as Unitary Patents, together with all national validations, national parts, national designations, and any extensions or validations thereof in any EPC
              member state or any extension or validation state;</font></font></div>
        <div style="text-align: left; margin-left: 54pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
            </font></font></div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">any European patent application or European patent that claims priority, directly or indirectly, in whole or in part, to: (i) any patent or application identified in clauses (a) or (b), or (ii) any priority application to which a
              patent or application identified in clauses (a) or (b) claims priority, in each case to the extent controlled by Genevant,</font></font> Arbutus, or any of their respective Affiliates; and</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 54pt;"> <br>
        </div>
        <div style="text-align: left; margin-left: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">any divisionals (including all generations
              thereof), substitutions, reissues, reexaminations, amendments, supplementary protection certificates, pediatric extensions, patent term extensions, and any other extensions or restorations of term relating to any of the foregoing.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 45pt;">For purposes of this definition, &#8220;controlled&#8221; means that Genevant, Arbutus, or any of their respective Affiliates (i) owns the relevant EPO
          Patent Right, in whole or in part, or (ii) has the legal right to license or enforce such EPO Patent Right without the consent of any Third Party and without any obligation to make any payment to any Third Party (for clarity, excluding payments
          to employees while employed by such Party or any of its Affiliates).</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 54pt;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2432b3b8bd7046d99a1314c6ec0c75f2">

            <tr>
              <td style="width: 18pt;">&#160;</td>
              <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 27pt;">1.9</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Ex-US Litigation&#8221; means the following proceedings:</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9662118950bb4934abfa03e36cf40fb7">

            <tr>
              <td style="width: 45pt;">&#160;</td>
              <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 27pt;">1.9.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Canada: Federal Court of Canada File No. T-704-25, for infringement of Canadian Patent No. 2,721,333;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9d02d3fdc78a4182a1ee05d759d3e504">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.9.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Japan: Tokyo District Court Case No. 2025 (Wa) 70079, for infringement of Japanese Patent No. 5,475,753;</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">3</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfc1fe83de9e644ada219d65276155415">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.9.3</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Switzerland: Case O2025 002, for infringement of European Patent 2279254;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z171af1f6244348c09b82be8b09aca6f3">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.9.4</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Case UPC_CFI_191/2025 (formerly Case 10280/2025), for infringement of European Patent 2279254;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5d0eebd004b47678a8ec109e8b0039d">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.9.5</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Case UPC_CFI_192/2025 (formerly Case 10284/2025), for infringement of European Patent 4241767;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za39147f20d254d5ebb632b8565b00804">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.9.6</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Moderna&#8217;s opposition proceedings before the European Patent Office concerning EP 2279254; and</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z86a42eadb45b4c3286802d7f9f1828e9">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.9.7</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Moderna&#8217;s opposition proceedings before the European Patent Office concerning EP 4241767.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5688304a87d5400f99f344583bc6388a">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.10</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Final Non-Appealable Judgment&#8221; means a judgment, order, or decree of a court of competent jurisdiction as to which: (a) no appeal, petition for rehearing or rehearing <font style="font-family: 'Times New Roman'; font-style: italic;">en banc</font>, or petition for writ of certiorari is pending; and (b) the time for filing any such appeal or petition has expired.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a24282392a7490bb02cc2a258b30741">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.11</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Genevant/Arbutus Patent Rights&#8221; means: (a) the Asserted US Patents; (b) Canadian Patent No. 2,721,333, Japanese Patent No. 5,475,753, European Patent 2279254, and European Patent 4241767 (the
                  &#8220;Asserted Ex-US Patents&#8221; and, together with the Asserted US Patents, the &#8220;Asserted Patents&#8221;); <a name="z_Hlk224719555"></a>(c) on a country-by-country basis, with respect to any country anywhere in the world, all other Patents with an
                  effective filing date before the Effective Date controlled by Genevant, Arbutus or any of their respective Affiliates that would, in the absence of the license granted under this Agreement, be infringed by the manufacture, use,
                  distribution, offer for sale, sale, import, or export of any Moderna Licensed Product; [***] and (e) any continuations, continuations-in-part, divisionals, re-examinations, re-issues, extensions, and foreign counterparts of any of the
                  Patents set forth in clauses (a) through (d). [***]</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d2123ea65a7467d9af41a0b9bbbecf9">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 28.8pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.12</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Moderna Licensed Products&#8221; means: SPIKEVAX (COVID-19 vaccine, mRNA); mNEXSPIKE (COVID-19 vaccine, mRNA); mRESVIA (Respiratory Syncytial Virus vaccine); and any other mRNA vaccine, including
                  those in development, that includes an SM-102-based LNP formulation against an infectious disease and is or will be either (i) licensed or authorized according to a Regulatory Application filed by Moderna or (ii) sold by or on behalf of
                  Moderna or its applicable Affiliate as Moderna&#8217;s or the Affiliate&#8217;s own product.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">4</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc769def264564997a1032ee64e85d017">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.13</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Patents&#8221; means (i) all classes or types of patents in any country or jurisdiction, including utility patents, utility models, design patents, invention certificates, reexamination certificates,
                  and reissue patents; and (ii) all applications for all classes and types of patents in any country or jurisdiction, including provisional applications, nonprovisional applications, continuations, divisionals, and continuations-in-part.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z66cd41c97c924ffcb89fa9ac74d758b5">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.14</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Person&#8221; means an individual, trust, corporation, partnership, joint venture, limited liability company, association, unincorporated organization or other legal or governmental entity.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf92add5c4c444370aea666939e5a8a15">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.15</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Regulatory Application&#8221; means an application for Emergency Use Authorization or a Biologics License Application submitted to FDA (or other application seeking approval to market a pharmaceutical
                  product including a foreign equivalent), and any supplements, amendments, or replacements thereto.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e653d75716f4735ba0ee39ce3876330">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.16</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">&#8220;Third Party&#8221; means a Person that is not a Party and is not an Affiliate of a Party.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb7b3ef8d99ff40dcb4ae501ba54664d4">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>Releases and Dismissals</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7d7f59b22d5d430fb7ffe9cf341ba125">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mutual Release</u></font><font style="font-size: 10pt;">. Except as set forth in Section 2.1.1, effective upon
                    the payment in full by Moderna of the noncontingent lump sum payment in accordance with Section 3.1, each Party, on behalf of itself, its Affiliates, shareholders, directors, officers, employees, agents, representatives, assigns,
                    predecessors, and successors, hereby fully, finally and irrevocably releases, relinquishes, acquits and discharges each other Party and its Affiliates, and each of their respective directors, officers, employees, agents,
                    representatives, heirs, assigns, shareholders, importers, manufacturers, distributors, suppliers, service providers, collaboration partners, licensees, insurers and each of their predecessors and successors of and from any and all
                    pending and potential claims, counterclaims, demands, all manner of actions, causes of action, suits, defenses, judgments, settlements, debts, offsets, accounts, damages, losses, liabilities, costs, expenses (including expert fees),
                    interest, punitive damages, reasonable attorneys&#8217; fees and other damages or costs of whatever nature, whether known or unknown, pending or future, certain or contingent (collectively, &#8220;Claims&#8221;), both at law and in equity, suspected or
                    unsuspected, accrued or unaccrued, in the case of each of the foregoing based on activities on or before the Effective Date which relate in any way to: (i) the US Litigation, including the claims asserted in the US Litigation; (ii) the
                    Ex-US Litigation, including the claims asserted in the Ex-US Litigation; and (iii) the manufacture, use, distribution, development, offer for sale, sale, import, or export of the Moderna Licensed Products or components thereof,
                    including any claims for infringement of any of the Genevant/Arbutus Patent Rights in any jurisdiction in which the Genevant/Arbutus Patent Rights exist. For clarity, neither the releases set forth in this Section 2.1 nor any other
                    provision of this Agreement shall prevent any Party from bringing an action or otherwise taking steps to enforce this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">5</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z99d385c394c641f69ba4bb1fc522f2dd">

            <tr>
              <td style="width: 45pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.1.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Limitation on Release of Claims Regarding the &#167; 1498 Disputed Matter</u></font><font style="font-size: 10pt;">.
                    The Parties acknowledge that pursuant to the stipulated judgment in the US Litigation and subject to Section 2.5, Moderna may appeal from the stipulated judgment solely with respect to the &#167; 1498 Disputed Matter. As of the Effective
                    Date, the release provided in Section 2.1 does not extend to the Disputed Doses. If, after the Effective Date, Moderna pays in full the contingent lump sum provided in Section 3.2 and has exhausted or forfeited any remaining appellate
                    rights concerning the decision that triggered its obligation to pay the contingent lump sum, then the release provided in Section 2.1 shall thereupon extend to the applicable Disputed Doses for which there is a Final Non-Appealable
                    Judgment affirming the &#167; 1498 Judgment in its entirety or otherwise holding that &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna for either or both of direct infringement and indirect infringement. If a Final
                    Non-Appealable Judgment holds that &#167; 1498(a) bars Genevant/Arbutus&#8217; claims with respect to all or some of the Disputed Doses, the release in Section 2.1 shall extend to those Disputed Doses as to which &#167; 1498(a) was found to bar
                    Genevant/Arbutus' claims, regardless of whether no contingent lump sum payment, or only a partial contingent lump sum payment, was required or made under Section 3.2. The release provided in Section 2.1 (including this Section 2.1.1)
                    (i) does not extend to the United States Government, and (ii) does not result in, and shall not be construed to result in, any impairment, waiver, release or other limitation on Genevant&#8217;s or Arbutus&#8217; (or any of their respective
                    Affiliates&#8217;) right to pursue any claim against the United States Government with respect to such products. Moderna shall not take any position or make any argument that is contrary to the limitations of the release, including clauses
                    (i) and (ii) immediately above. Moderna&#8217;s compliance with its contractual obligations under the C-100 Contract to the U.S. Government, including compliance with <font style="font-family: 'Times New Roman'; color: rgb(50, 50, 50);">FAR
                      52.227-2, </font>does not violate any term of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zde123f5717fb44449bc2d2a34c3028d7">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Waiver of Right to Assert Unknown Claims</u></font><font style="font-size: 10pt;">. Each Party hereby expressly
                    waives any and all provisions, rights and benefits conferred by &#167; 1542 of the California Civil Code (which provides that &#8220;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist
                    in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party&#8221;), or by any law or principle of common law that is
                    similar, comparable or equivalent to &#167; 1542 of the California Civil Code, with respect to the Claims released in Section 2.1.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba80bbbec84c4e29997820fad8467826">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Dismissal of the US Litigation and Ex-US Litigation</u></font><font style="font-size: 10pt;">. Within one (1)
                    Business Day of the Effective Date, the Parties shall cause their counsels to execute and promptly file, and shall reasonably cooperate and take other reasonable actions to effectuate, stipulated judgments and stipulations of dismissal
                    (substantially in the forms included in Exhibit 2.3 hereto) for the respective courts or tribunals to enter judgment or dismiss with prejudice or withdraw (as the case may be) all claims in the US Litigation and Ex-US Litigation, with
                    each Party to bear its own fees and costs.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">6</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z89c2f5680015489d9ec989d6a848bad9">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Patent Challenges</u></font><font style="font-size: 10pt;">. Moderna shall not, and shall cause its
                    Affiliates not to, voluntarily challenge or assist any Third Party in challenging the infringement, validity, or enforceability of any of the Asserted US Patents, any U.S. Patents that claim priority to the same applications as the
                    Asserted US Patents (the &#8220;Related Asserted US Patents&#8221;), or U.S. Patent Nos. 8,492,359, 11,298,320, and 11,318,098 (collectively with the Asserted US Patents and the Related Asserted US Patents, the &#8220;Specified Patents&#8221;), except if any
                    Specified Patent is asserted or threatened to be asserted (i) against Moderna or any of its Affiliates, or (ii) against any Related Third Party within the scope of any license, release, or covenant granted under this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25f02fca7f974041a577f0d9701ef5a4">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.4.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Freedom to Operate</u></font><font style="font-size: 10pt;">. Moderna, its Affiliates, and their collaboration
                    partners may initiate or participate in any validity challenge (including IPR, PGR, reexamination, or opposition) concerning Genevant/Arbutus Patent Rights&#8212;other than Specified Patents&#8212;involving claims that are not expressly limited to
                    the field of use of the Moderna Licensed Products and such challenge relates to Moderna products, technology, or activities&#8212;other than a Moderna Licensed Product&#8212;Moderna shall not be required to identify or specify any particular
                    product in connection with such challenge, and any such challenge shall not constitute an admission of validity, enforceability, or infringement of the Genevant/Arbutus Patent Rights.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z526be8b89ed44163b8011dbf05795158">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.4.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Admissions</u></font><font style="font-size: 10pt;">. Nothing in this Agreement constitutes an admission by
                    any Party of the validity or invalidity of any Genevant/Arbutus Patent Right, of direct or indirect infringement of those patents, or of any issue relating to the US Litigation or Ex-US Litigation. Further, the consent to enter judgment
                    in Exhibit 2.3 for the US Litigation is entered into by Moderna based on the disclosures of the asserted patents&#8217; specifications, the relevant priority dates, the Court&#8217;s claim construction, and the parties&#8217; contentions and expert
                    opinions, the specific asserted relevant prior art, the specific prior related proceedings, and the asserted claims in the patents.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z778c396d4e744e938a355b6ef221b9ed">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.4.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successors and Acquired Entities</u></font><font style="font-size: 10pt;">. This Section 2.4 does not apply to
                    (i) an assignee or transferee under Section 7.6 that is not an Affiliate of a Party, or (ii) any entity acquired by Moderna or its Affiliates after the Effective Date, with respect to any challenge in which that entity was participating
                    prior to the closing of such acquisition.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39978c13bc1d44e9a3556150d54b7743">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.4.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Compelled Activities</u></font><font style="font-size: 10pt;">. Nothing in this Section 2.4 prevents Moderna or
                    its Affiliates from complying with discovery requests, testifying at depositions, serving as a witness, complying with court or, subject to Section 2.6, government directives, complying with applicable laws or regulations, or complying
                    with contractual obligations (including Moderna&#8217;s obligations under the C-100 Contract, including FAR 52.227-2).</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">7</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z97dd6cb0874f479a8d95835ce105674d">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.5</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Appeal of the &#167; 1498 Judgment</u></font><font style="font-size: 10pt;">. Pursuant to the stipulated judgment to
                    be entered in the US Litigation, Moderna will preserve its right to appeal solely with respect to the &#167; </font>1498 Disputed Matter. For the avoidance of doubt, no Party shall challenge on appeal the district court&#8217;s finding that
                  &#8220;vaccine doses that the Government acquired and distributed to its own employees&#8221; (quoted from D.I. No. 697, at 15) are subject to 28 U.S.C. &#167; 1498(a) and Moderna is not liable for infringement. Moderna may challenge on appeal only the
                  district court&#8217;s conclusions with respect to the &#167; 1498 Disputed Matter. In conducting these appellate proceedings at the Federal Circuit (both first-instance and following any remand), no Party will (without the consent of all other
                  Parties) seek any extension [***]. In proceedings before the Supreme Court, no Party shall seek extension on a cert petition, and during the Supreme Court merits stage, no Party shall seek any extensions on merits briefing without first
                  confirming with the Court that the extensions will not affect which argument session the case will be heard. Any failure to comply with the preceding sentence will be deemed a material breach of this Agreement. If any Party moves for or
                  requests expedited oral argument in the first-instance appeal before the Federal Circuit and any subsequent appeal before the Federal Circuit following remand or other further proceedings, all other Parties shall join or support such
                  motion or request upon written notice thereof from the moving Party.</div>
              </td>
            </tr>

        </table>
        <br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf206bf9a444540b88a990ee90346c4a4">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.6</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Moderna&#8217;s Role in any Court of Federal Claims Action Concerning the C-100</u></font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman';"><u>Contract Doses</u></font>. In any claim Genevant or Arbutus (or any of their Affiliates) files against the United States Government related to doses sold under the C-100 Contract,
                    to the extent Moderna is served with any discovery requests or subpoenas by Genevant, Arbutus, or the U.S. Government, Moderna shall reasonably comply by providing proportional discovery pursuant to a protective order that Moderna
                    agrees to. Notwithstanding anything herein to the contrary, the provision of discovery in response to a lawful discovery request or subpoena does not breach or otherwise violate the terms of this Agreement. Notwithstanding anything
                    herein to the contrary, Moderna shall have the right to comply with its contractual obligations under the C-100 Contract to the U.S. Government, including compliance with FAR 52.227-2, provided that Moderna shall not provide any
                    assistance to the United States Government in any claim against the United States Government related to doses sold under the C-100 Contract that it is not contractually obligated to provide, and compliance thereunder does not breach or
                    otherwise violate the terms of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z593552ea39454e7f8a208657681b1726">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>Payments to Genevant/Arbutus</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1e6f131450a449baa999aca2474097e2">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Noncontingent Lump Sum Payment</u></font><font style="font-size: 10pt;">. In consideration for the release and
                    dismissals set forth in Section 2, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, the noncreditable, nonrefundable sum of nine hundred fifty million United States Dollars (US $950,000,000.00) in
                    accordance with an allocation schedule to be provided to Moderna by Genevant on or before June 30, 2026. Said payment shall be made on or before July 8, 2026 [***].</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">8</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c1a83e1126d4077ba24ecb07f1ef9f5">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Contingent Lump Sum Payment</u></font><font style="font-size: 10pt;">. In consideration for the release and
                    dismissals set forth in Section 2.1.1 and without limitation of Section 3.3, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, the noncreditable, nonrefundable contingent lump sum payment specified in
                    one of Section 3.2.1, Section 3.2.2 or Section 3.2.3, should one be applicable.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbe4fa225b8aa46e2afcaad1484f9559a">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.2.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Full Affirmance Upon Final Non-Appealable Judgment</u></font><font style="font-size: 10pt;">: If there is a
                    Final Non-Appealable Judgment affirming the &#167; 1498 Judgment in its entirety, or otherwise holding that &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna for either or both of direct infringement and indirect infringement
                    for all of the Disputed Doses, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, one billion three hundred million United States Dollars (US $1,300,000,000.00), within ninety (90) days after such Final
                    Non-Appealable Judgment, plus interest calculated from the date that the Federal Circuit first issues a decision with respect to the &#167; 1498 Disputed Matter (if such decision was not a Final Non-Appealable Judgment) until the date of
                    payment under this Section 3.2.1, at the per annum rate of the lesser of: (i) [***] over the then-current US prime lending rate (as reported in the Wall Street Journal); or (ii) the maximum rate permitted by applicable law.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1947d8e0674e45ee97bafeebf8cb08fc">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.2.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mixed Outcome Payment Upon Final Non-Appealable Judgment</u></font><font style="font-size: 10pt;">: If Section
                    3.2.1 does not apply and there is a Final Non-Appealable Judgment holding that </font>&#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna for either or both of direct infringement and indirect infringement for a subset of
                  the Disputed Doses, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, a prorated amount of one billion three hundred million United States Dollars (US $1,300,000,000.00) that reflects the number of
                  Disputed Doses to which &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna. Payment shall be due within sixty (60) days after the Final Non-Appealable Judgment. The prorated amount shall be calculated by assigning equal value
                  to each dose, using the following formula:
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
                  </div>
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(Number of Disputed Doses to which &#167; 1498(a) does not bar) &#247; (493,757,200) &#215; US $1,300,000,000.00 = &#8220;Mixed Outcome Payment&#8221;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7946c79030e418aa9e76f1f45087314">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.2.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Payment Upon Forgone Appeal</u></font><font style="font-size: 10pt;">: If Moderna does not file a notice of
                    appeal within twenty-one (21) days of the district court's entry of the stipulated &#167; 1498 Judgment, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, one billion three hundred million United States
                    Dollars (US </font>$1,300,000,000.00) within ninety (90) days after such entry. If Moderna voluntarily dismisses a pending appeal, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, one billion three
                  hundred million United States Dollars (US $1,300,000,000.00) within ninety (90) days of such entry of filing for voluntary dismissal. Only if the voluntary dismissal was not by agreement of the Parties, interest shall be due or payable,
                  from the Effective Date through the payment date by Moderna under this Section 3.2.3, at the per annum rate of the lesser of: (i) [***] over the then-current US prime lending rate (as reported in the Wall Street Journal); or (ii) the
                  maximum rate permitted by applicable law. If the voluntary dismissal is made by agreement between the parties, no interest shall be due or payable by Moderna.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">9</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae85cc33a1e84f39a68dfb40ec3d89a8">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Interim Payments Pending Final Resolution</u></font><font style="font-size: 10pt;">: Because a Federal Circuit
                    decision may be subject to further appeal, rehearing, rehearing <font style="font-family: 'Times New Roman'; font-style: italic;">en banc</font>, certiorari, and/or remand proceedings, any payment made by Moderna pursuant to this
                    Section 3.3 prior to a Final Non-Appealable Judgment is an interim payment that is subject to refund or true-up as set forth below.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9214ef16f054d9984e457574be2fe0a">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.3.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Interim Payment upon Federal Circuit Full Affirmance</u></font><font style="font-size: 10pt;">: If there is a
                    decision of the Federal Circuit, by the initial panel, upon panel rehearing, or <font style="font-family: 'Times New Roman'; font-style: italic;">en banc</font>, affirming the &#167; 1498 Judgment in its entirety, or otherwise holding that
                    &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna as to either or both of direct infringement and indirect infringement, for all of the Disputed Doses, Moderna shall pay to Genevant, Arbutus, or their respective designees,
                    collectively, one billion three hundred million United States Dollars (US </font>$1,300,000,000.00) (the &#8220;Interim Affirmance Payment&#8221;) within ninety (90) days after such Federal Circuit decision. No interest shall be due or payable by
                  Moderna under this Section 3.3.1.</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; margin-right: 21.85pt; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 72pt;">If, following the Interim Affirmance Payment, a Final Non-Appealable Judgment affirms the &#167; 1498 Judgment in its entirety, or otherwise
          holds that &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna, as to either or both of Genevant/Arbutus&#8217; direct infringement claims and indirect infringement claims, for all of the Disputed Doses, the Interim Affirmance Payment shall
          be deemed to satisfy Moderna&#8217;s obligation under Section 3.2, and no further contingent lump sum payment shall be due. If, however, a Final Non-Appealable Judgment reverses the &#167; 1498 Judgment in its entirety, Genevant/Arbutus shall refund to
          Moderna the full amount of the Interim Affirmance Payment, plus interest calculated from the date the Interim Affirmance Payment was made by Moderna until the date of refund at the per annum rate of the lesser of: (i) [***] over the then-current
          US prime lending rate (as reported in the Wall Street Journal); or (ii) the maximum rate permitted by applicable law. Such refund shall be made by wire transfer of immediately available funds in accordance with instructions to be provided in
          writing by Moderna, within ninety (90) days after the date on which such Final Non-Appealable Judgment is entered. If the Final Non-Appealable Judgment results in a mixed outcome such that Section 3.2.2 applies, the Parties shall reconcile the
          Interim Affirmance Payment against the Mixed Outcome Payment, and Genevant/Arbutus shall refund any excess, plus interest as provided above, within ninety (90) days after such Final Non-Appealable Judgment.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">10</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zad46c6bb941a4993863d45a5314f4ef2">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.3.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mixed Outcome Subject to Further Proceedings</u></font><font style="font-size: 10pt;"> &#8211; <font style="font-family: 'Times New Roman';"><u>Interim Payment and Binding</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>Arbitration to Determine Interim Payment</u></font>: This Section 3.3.2 applies if: (a) the Federal
                    Circuit issues a decision that is not a Final Non-Appealable Judgment; (b) such decision holds that &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna for either or both of direct infringement and indirect infringement, as
                    to some, but not all, of the Disputed Doses; and (c) one or more Parties seek further appellate review or additional proceedings (including remand) that could alter the number of Disputed Doses to which &#167; 1498(a) is a bar (a &#8220;Mixed
                    Outcome Subject to Further Proceedings&#8221;).</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2d1f36126632459e95b135cea7d90eaa">

            <tr>
              <td style="width: 108pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">a.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Good-Faith Negotiation</u></font><font style="font-size: 10pt;">: Within [***] following a Mixed Outcome Subject
                    to Further Proceedings, the Parties shall engage in good-faith negotiations to agree upon the number of Disputed Doses subject to the initial decision and the corresponding interim payment amount, if any, that Moderna must pay pending
                    the outcome of subsequent proceedings. If the Parties reach agreement within such [***] period, Moderna shall pay the agreed-upon amount within [***] after such agreement. Payments made under this Section a are subject to refund and
                    additional payment under the True Up provisions of Section 3.6.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za0ca86d1809f468a8dc8ada1f206780f">

            <tr>
              <td style="width: 108pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">b.</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Binding Arbitration to Determine Interim Payment</u></font><font style="font-size: 10pt;">: If the Parties do
                    not reach agreement pursuant to Section a within the [***] negotiation period, either Party may invoke binding arbitration by written notice to the other Party within [***] following the expiration of the negotiation period. The
                    arbitration shall determine: (a) the prorated number of Disputed Doses for which Moderna is likely to prevail in obtaining a final judgment that &#167; 1498(a) bars Genevant/Arbutus&#8217; claim against Moderna for either or both of direct
                    infringement and indirect infringement; and (b) the corresponding interim payment amount, if any, that Moderna must pay pending the outcome of subsequent proceedings. [***]</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4776a7aaef84d9880ce5114c65d99b6">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Binding Arbitration Upon Delay of Federal Circuit Proceedings</u></font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">:</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z009a08b5bf81499ab6e86ca22d96b100">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.4.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Right to Invoke Arbitration</u></font><font style="font-size: 10pt;">: If the Federal Circuit has not issued a
                    first-instance decision by a merits panel on the &#167; 1498 Judgment within twenty-four (24) months of Moderna&#8217;s filing of the notice of appeal, Genevant/Arbutus may invoke binding arbitration by written notice to Moderna to determine
                    whether Moderna has engaged in conduct outside of standard appellate advocacy that contributed materially to a material delay of the Federal Circuit proceedings.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">11</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za6257468133841a391ed2428abd21324">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.4.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Standard for Determination</u></font><font style="font-size: 10pt;">: The arbitrator shall determine solely
                    whether Moderna engaged in conduct outside of standard appellate advocacy that contributed materially to a material delay of the Federal Circuit proceedings. For the avoidance of doubt, the following are examples of standard appellate
                    advocacy that shall not qualify as Moderna engaging in conduct contributing to material delay: (i) filing briefs in accordance with the standard Federal Circuit briefing schedule; (ii) efforts to generate and coordinate the filing of
                    amicus curiae briefs regardless of the number of such briefs; (iii) responding to court orders or inquiries in accordance with the Federal Circuit&#8217;s instructions, including relating to its jurisdiction to entertain the appeal; and (iv)
                    delays caused by the court&#8217;s own scheduling, internal processes, or backlog. In determining whether Moderna engaged in conduct outside of standard appellate advocacy that contributed materially to a material delay of the Federal Circuit
                    proceedings, the arbitrator shall subtract from the asserted period of material delay any period of delay attributable to the conduct of Genevant or Arbutus and any period of delay attributable to the court.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z655d37478d504e6ca9de3d7af2a9457b">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.4.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Payment Obligation Upon Finding of Material Delay</u></font><font style="font-size: 10pt;">: If the arbitrator
                    determines that Moderna materially delayed the Federal Circuit proceedings and is thus responsible for the absence of first-instance decision within 24 months, Moderna shall pay to Genevant, Arbutus, or their respective designees,
                    collectively, one billion three hundred million United States Dollars (US $1,300,000,000.00) within ninety (90) days after the arbitrator&#8217;s decision. Such payment shall be subject to refund, including interest, in accordance with the
                    provisions of Section </font>3.10 as if it were a contingent lump sum payment made under Section 3.2.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a0753a553a345b7927c6d4ddddb8625">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.4.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Costs of Delayed Arbitration</u></font><font style="font-size: 10pt;">: The non-prevailing Party shall pay the
                    prevailing Party&#8217;s reasonable attorneys&#8217; fees and costs, as well as the fees and expenses of the arbitrator, as well as a lump sum of [***] as a mutually agreed reasonable estimate of the intangible costs incurred by the prevailing
                    Party in executive time, overhead, and opportunity costs associated with the arbitration.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfbc8b5775c4b46f1b34fec3cd0922066">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.5</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Arbitration Procedures</u></font><font style="font-size: 10pt;">: Any arbitration under Section 3.3.2(b) or
                    Section 3.4 shall be conducted in accordance with the arbitrator selection procedures set forth in Section</font></div>
              </td>
            </tr>

        </table>
        <font style="font-size: 10pt;"><br>
        </font>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="2b2f12043a124c41a9334823c51effee" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 45pt;"></td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.5.1</td>
              <td style="vertical-align: top; text-align: left;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">and the arbitration procedures and schedule set forth in Section 3.5.2. Additionally, the non-prevailing Party
                    shall pay the prevailing Party&#8217;s reasonable attorneys&#8217; fees and costs, as well as the fees and expenses of the arbitrator.</font></font></td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z83313dc9f98e48cb84f1b8ea89381bb2">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.5.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Arbitrator Selection</u></font><font style="font-size: 10pt;">: Within [***] after the notice invoking
                    arbitration, the Parties shall mutually agree upon a single neutral arbitrator with experience in patent litigation matters. If the Parties cannot agree within such period, each of Moderna and Arbutus and Genevant together shall, within
                    [***] thereafter, designate one candidate arbitrator, and those two candidates shall jointly select the arbitrator within [***].</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48be3fad1bb44a0b878bb109dee1e60a">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.5.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Arbitration Procedures and Schedule</u></font><font style="font-size: 10pt;">:</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 45pt;">The arbitration shall proceed on the following expedited schedule:</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">12</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <div style="text-align: left; text-indent: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Opening Briefs</u></font>: Each Party shall submit an opening brief of no more than ten (10) pages within [***] of the arbitrator&#8217;s appointment. Briefs shall be submitted simultaneously
              (cross-briefing).</font></font></div>
        <div style="text-align: left; text-indent: 54pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
            </font></font></div>
        <div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 45pt;">(b) &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Responsive Briefs</u></font><font style="font-size: 10pt;">: Each Party shall submit a responsive brief of no more than ten</font> (10) pages within [***] of the exchange of opening briefs. Responsive briefs shall be submitted simultaneously (cross-briefing).</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 54pt;"> <br>
          </div>
        </div>
        <div style="text-align: left; text-indent: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Oral Argument</u></font>: The arbitrator may, in the arbitrator&#8217;s sole discretion, convene oral argument. If oral argument is held, it shall occur within [***] of the submission of
              responsive briefs.</font></font></div>
        <div style="text-align: left; text-indent: 54pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
            </font></font></div>
        <div style="text-align: left; text-indent: 45pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Decision</u></font>: The arbitrator shall issue a written decision within [***] of the submission of responsive briefs, or within [***] of oral argument if oral argument is held. The
              Parties agree not to submit, cite, or reference the arbitrator&#8217;s decision to any court adjudicating any appeal or remand from any appeal of the US Litigation.</font></font></div>
        <div style="text-align: left;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
            </font></font></div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11da9cbba7fb4c799b67ea9e936817b8">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.5.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Standard for Arbitrator&#8217;s Determination in Arbitration Pursuant to Section</u></font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman';"><u>3.3.2(b)</u></font>:</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 45pt;">The arbitrator shall determine: (a) the Party most likely to prevail in obtaining a Final Non-Appealable Judgment as to whether &#167; 1498(a)
          bars Genevant/Arbutus&#8217; claim against Moderna as to either or both of direct infringement and indirect infringement, as to the disputed portion of the Disputed Doses; and (b) the proportion of the Disputed Doses as to which such Party is likely to
          prevail. The arbitrator shall base this determination solely on the applicable law and precedent that would govern the Federal Circuit and any court or tribunal with jurisdiction over subsequent proceedings, the record developed in the US
          Litigation and appellate proceedings, and the reasoning set forth in any judicial decisions issued to date.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z207bac23494c42bc9cf81789d39e4c12">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.5.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Interim Payment Obligation following Arbitration Pursuant to Section 3.3.2(b)</u></font><font style="font-size: 10pt;">: Within sixty (60) days after the arbitrator's decision, Moderna shall pay to Genevant, Arbutus, or their respective designees, collectively, an amount calculated as follows:</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 144pt;">(Number of Disputed Doses - Number of Disputed Doses for which the arbitrator determines Moderna is likely to prevail that &#167; 1498(a) is a bar to
          Genevant/Arbutus&#8217; claim against Moderna) &#247; (493,757,200) &#215; US</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 144pt;">$1,300,000,000.00 = interim payment</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 45pt;">If the arbitrator determines that Moderna is likely to prevail that &#167; 1498(a) is a bar to Genevant/Arbutus&#8217; claim against Moderna as to all
          Disputed Doses, no interim payment shall be due.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 54pt;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5e29bad4d9144edb67ef85d475c56ad">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.6</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>True-Up Upon Final Non-Appealable Judgment</u></font><font style="font-size: 10pt;">: Upon entry of a Final
                    Non-Appealable Judgment resolving the &#167; 1498 Disputed Matter:</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">13</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc50cc5d98a2845d1ae8744e62a27382e">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(a)</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Underpayment</u></font><font style="font-size: 10pt;">: If the Final Non-Appealable Judgment determines that
                    Moderna is liable for a greater number of Disputed Doses than reflected in any interim payment, Moderna shall pay the difference to Genevant, Arbutus, or their respective designees within sixty </font>(60) days after such judgment,
                  plus interest calculated from the date that such interim payment was made until the date of payment under this Section 3.6(a), at the per annum rate of the lesser of: (i) [***] over the then-current US prime lending rate (as reported in
                  the Wall Street Journal); or (ii) the maximum rate permitted by applicable law.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1e1a7d84d7f14ca0b4806f2d3fae7aed">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(b)</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Overpayment</u></font><font style="font-size: 10pt;">: If the Final Non-Appealable Judgment determines that
                    Moderna is liable for fewer Disputed Doses than reflected in any interim payment (including zero doses), Genevant/Arbutus shall refund the excess amount to Moderna within sixty (60) days after such judgment, plus interest calculated
                    from the date that such interim payment was made until the date of payment under this Section 3.6(b), at the per annum rate of the lesser of:</font></div>
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">(i) [***] over the then-current US prime lending rate (as reported in the Wall Street Journal); or (ii) the maximum rate permitted by applicable law.<font style="font-size: 10pt;"> </font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z163aef58ea48417baff4b3353e6c3eed">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.7</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Remand Proceedings</u></font><font style="font-size: 10pt;">: If the &#167; 1498 Judgment is vacated or reversed and
                    remanded to the district court for further proceedings, the issues before the district court shall be limited to the issues that the Federal Circuit remands to the district court. On remand, the Parties shall not challenge the validity,
                    enforceability, or claim scope of any Genevant/Arbutus Patent Right, or whether the physical composition of Disputed Doses falls within the scope of the asserted claims. However, if the Federal Circuit determines that &#167; 1498(a) bars
                    Genevant/Arbutus's claims for direct infringement but does not bar Genevant/Arbutus&#8217; claims for indirect infringement for any Disputed Doses, Moderna shall be permitted to fully litigate on remand the number of Disputed Doses, if any,
                    for which Moderna is liable for indirect infringement, including whether the predicate acts of direct infringement necessary to establish indirect infringement liability exist with respect to any such Disputed Doses.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z239a49bb85c145c9b4b0596fd28a5737">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.7.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Payment Upon Adverse Remand Decision:</u></font><font style="font-size: 10pt;"> If (a) the &#167; 1498 Judgment is
                    vacated or reversed and remanded, (b) the district court determines on remand that &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claims with respect to any portion of the Disputed Doses, then Moderna shall, within ninety (90) days of such
                    decision, pay to Genevant, Arbutus, or their respective designees, collectively, an interim payment (the &#8220;Interim Remand Payment&#8221;) equal to:</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt; margin-left: 144pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 144pt;">(Number of Disputed Doses to which the district court determines &#167; 1498 does not bar claims) &#247; (493,757,200) &#215; US $1,300,000,000.00 = Interim Remand
          Payment</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">Any Interim Remand Payment shall be subject to refund or true-up upon entry of a Final Non-Appealable Judgment in accordance with Section 3.6.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f5e92b243954e7fb39e3dc3bdc8c7fe">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 28.8pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.8</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Method of Payment</u></font><font style="font-size: 10pt;">: [***]<a name="z_Hlk224751756"></a></font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f13bde2392f4b1ca32e62c8ba40dbeb">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 28.8pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.9</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">[***]</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">14</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z46deacc47c08470e88c0c71b507dd52a">

            <tr>
              <td style="width: 18pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.10</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Return of the Contingent Lump Sum Payment</u></font><font style="font-size: 10pt;">: If Genevant/Arbutus
                    receives a contingent lump sum payment pursuant to Section 3.2 based on a finding that &#167; 1498(a) does not bar Genevant/Arbutus&#8217; claim against Moderna as to a subset of Disputed Doses and there is subsequently a Final Non-Appealable
                    Judgment holding that &#167; 1498(a) does bar Genevant/Arbutus&#8217; claim against Moderna as to that subset of doses, Genevant/Arbutus shall refund to Moderna the corresponding portion of the contingent lump sum payment, plus interest calculated
                    from the date of Moderna&#8217;s payment until the date of refund at the per annum rate of the lesser of: (i) [***] over the then-current US prime lending rate (as reported in the Wall Street Journal); or (ii) the maximum rate permitted by
                    applicable law. Repayment shall be made by wire transfer within ninety (90) days of the date such amount becomes due.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75da5d5b0976440b8ead58167f8c3552">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.10.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Genevant/Arbutus Financial Covenant Protection</u></font><font style="font-size: 10pt;">. Any contingent lump
                    sum payment pursuant to Section 3.2 or any interim payment pursuant to Section 3.3, in each case that remains subject to a potential repayment obligation under this Agreement (such payment, a &#8220;Potentially Refundable Payment&#8221;) shall be
                    subject to the ongoing requirements set forth in this Section 3.10.1. Genevant and Arbutus shall, from the date that such Potentially Refundable Payment becomes due until the earlier such time as any Genevant/Arbutus repayment
                    obligation has been fully and finally extinguished, comply with the following requirements.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8fcc6685d4804f4fa302f5f15c44646e">

            <tr>
              <td style="width: 45pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(a)</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Financial Assurance</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f65540c03984acd8743ea5b0d9cf944">

            <tr>
              <td style="width: 54pt;">&#160;</td>
              <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 27pt;">(i)</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Genevant</u></font><font style="font-size: 10pt;">. Moderna shall have no obligation to make any Potentially
                    Refundable Payment unless and until the Approved Financial Assurances have been provided to Moderna sufficiently in advance for Moderna to make a timely payment. Prior to the payment by Moderna to Genevant (or its designee) of any
                    Potentially Refundable Payment, Genevant shall provide Moderna with one or more of the following forms of alternative financial assurance (&#8220;Approved Financial Assurances&#8221;), in an aggregate amount not less than the Potentially Refundable
                    Payment then due to Genevant (or its designee):</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">15</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z250c0d4bf4954e9b9f9c015bd8b803be">

            <tr>
              <td style="width: 81pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(A)</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">an irrevocable surety bond issued by a surety company rated at least &#8220;A-&#8221; by A.M. Best (or an equivalent rating by a nationally recognized rating agency);</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z30dc8d657e704963aab1f6d235110b20">

            <tr>
              <td style="width: 81pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(B)</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">one or more irrevocable standby letters of credit issued by a United States commercial bank having total assets of not less than [***];</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9dc2b8d7d2a4f1c94061718fd3be494">

            <tr>
              <td style="width: 81pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(C)</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">a cash escrow deposit held by an independent, nationally recognized escrow agent pursuant to an escrow agreement in form and substance reasonably acceptable to Moderna;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8ce2f4749e874433b45daf38426fcb24">

            <tr>
              <td style="width: 81pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(D)</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">a segregated account over which Genevant shall grant Moderna a perfected, first-priority security interest, which shall be subject to customary restrictions reasonably acceptable to Moderna; or</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93eff4cc588a498ebf42cf94084b3f77">

            <tr>
              <td style="width: 81pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(E)</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">a Parent Guaranty in accordance with the terms of Section 3.10.1(ii) below; or</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z42b72c88ce5c4ea0a33868073b0ed2e6">

            <tr>
              <td style="width: 81pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(F)</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such other form of financial assurance as is reasonably acceptable to Moderna.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z31a57fdffab5495c98c35c8f2d42cde1">

            <tr>
              <td style="width: 54pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(ii)</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Roivant Guaranty</u></font><font style="font-size: 10pt;">. In the case Genevant chooses clause (a)(i)(E) as an
                    Approved Financial Assurance, with respect to all or any portion of the Potentially Refundable Payment due to Genevant (or its designee), Roivant Sciences Ltd., a Bermuda exempted limited company (&#8220;Roivant&#8221;) must execute and deliver to
                    Moderna an unconditional, irrevocable guaranty (the &#8220;Parent Guaranty&#8221;), in a form reasonably acceptable to Moderna, pursuant to which Roivant unconditionally and irrevocably guarantees the repayment obligations of Genevant under this
                    Agreement with respect to the applicable portion of such Potentially Refundable Payment (the &#8220;Guaranteed Refundable Payment Amount&#8221;). Any such Parent Guaranty shall:</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div>
          <div style="font-family: 'Times New Roman'; margin-left: 117pt;">(1) be absolute and unconditional;</div>
          <div style="font-family: 'Times New Roman'; margin-left: 117pt;"> <br>
          </div>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 117pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(2)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">remain in full force and effect until the earlier of (i) the date on which Moderna&#8217;s right to repayment from Genevant of the Guaranteed Refundable Payment Amount has been fully and finally extinguished, and</font></font> (ii) the
          date on which Genevant (or Roivant on its behalf) has repaid to Moderna the full amount of the Guaranteed Refundable Payment Amount due from Genevant hereunder (the &#8220;Parent Guaranty Period&#8221;);</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 117pt;"> <br>
        </div>
        <div>
          <div style="font-family: 'Times New Roman'; margin-left: 117pt;">(3) not be subject to any defenses, set-offs, counterclaims, or conditions;</div>
          <div style="font-family: 'Times New Roman'; margin-left: 117pt;"> <br>
          </div>
        </div>
        <div style="text-align: left; margin-left: 117pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(4)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">waive any right of Roivant to require Moderna
              to proceed first against Genevant or any collateral; and</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">16</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <div style="text-align: left; margin-left: 117pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(5)</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">provide that Roivant shall pay all amounts
              due within thirty (30) days after Moderna&#8217;s written demand therefor following the failure of Genevant to make any required repayment when due.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">If, at any time during the Parent Guaranty Period, Roivant fails to maintain cumulative cash and cash equivalents, investments (current and
          non-current), and outstanding liquidity related to undrawn loan facilities (determined in accordance with generally accepted accounting principles as reported in Roivant&#8217;s most recent quarterly or annual filing with the SEC or equivalent
          regulatory authority), equal to at least two point three (2.3) times the Guaranteed Refundable Payment Amount, then Roivant or Genevant must, within thirty (30) days after such failure, provide Moderna with one or more of the Approved Financial
          Assurances (other than a Parent Guaranty) with respect to Guaranteed Refundable Payment Amount.</div>
        <div style="font-size: 10pt; margin-left: 81pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">Roivant shall provide Moderna with written notice within [***] after becoming aware that Roivant&#8217;s cumulative cash and cash equivalents, investments
          (current and non-current), and outstanding liquidity related to undrawn loan facilities has fallen below the threshold described in this Section 3.10.1(a)(ii).</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z24f8479adef54fea991eb100680554f7">

            <tr>
              <td style="width: 54pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(iii)</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Arbutus</u></font><font style="font-size: 10pt;">. If, at any time after the date that a Potentially Refundable
                    Payment becomes due to Arbutus (or its designee), until the earlier of (1) the date on which Moderna&#8217;s right to repayment of any portion of the Potentially Refundable Payment from Arbutus has been fully and finally extinguished, and (2)
                    the date on which Arbutus has repaid to Moderna the full amount due by Arbutus under this Agreement with respect to a Potentially Refundable Payment, Arbutus fails to maintain cumulative cash and cash equivalents, investments (current
                    and non-current), and outstanding liquidity related to undrawn loan facilities (determined in accordance with generally accepted accounting principles as reported in Arbutus&#8217; most recent quarterly or annual filing with the SEC or
                    equivalent regulatory authority after giving effect, on a <font style="font-family: 'Times New Roman'; font-style: italic;">pro forma </font>basis, to the portion of the Potentially Refundable Payment payable to Arbutus (or its
                    designee) in accordance with Section 3.1 and not yet paid), of at least two point three times the amount of the Potentially Refundable Payment paid to Arbutus (or its designee), Arbutus shall, within [***] after such failure, provide
                    Moderna with one or more of Approved Financial Assurances, in an aggregate amount not less than the Potentially Refundable Payment then outstanding.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 81pt;">Arbutus shall provide Moderna with written notice within [***] after becoming aware that Arbutus&#8217; cumulative cash and cash equivalents, investments
          (current and non-current), and outstanding liquidity related to undrawn loan facilities has fallen below the threshold described in this Section 3.10.1(a)(ii).</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">17</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0d2c2db5a4341e5bb27cb088bf37f7f">

            <tr>
              <td style="width: 54pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(iv)</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Any Approved Financial Assurance provided pursuant to this Section 3.10.1(a) shall name Moderna or its designee as beneficiary and shall remain in effect until the earlier of (A) the date on
                  which Moderna&#8217;s applicable right to repayment has been fully and finally extinguished, or (B) the date on which Genevant (or Roivant on its behalf) or Arbutus, as applicable, has repaid to Moderna the applicable full amount due. Genevant
                  or Arbutus, as applicable, shall provide Moderna with prompt written notice of the form of Approved Financial Assurance selected and reasonable documentary evidence thereof.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z57bc74a294c54025a13a8d8b69ab1263">

            <tr>
              <td style="width: 45pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(b)</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Effect of Failure to Satisfy Financial Covenants</u></font><font style="font-size: 10pt;">. If Genevant fails to
                    deliver financial assurance pursuant to Section 3.10.1(a)(i) when due, Moderna shall deposit the Potentially Refundable Payment into an escrow account with an independent, nationally recognized escrow agent, to be released to Genevant
                    (or its designee) upon delivery of financial assurance pursuant to Section 3.10.1(a)(i). If Arbutus fails to deliver financial assurance pursuant to Section 3.10.1(a)(iii) when due, Moderna shall deposit the portion of the Potentially
                    Refundable Payment due to Arbutus (or its designee) into an escrow account with an independent, nationally recognized escrow agent, to be released to Arbutus (or its designee) upon delivery of financial assurance pursuant to Section
                    3.10.1(a)(iii).</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaf11885dafc241f59e79ae90023d160f">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.11</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Moderna Financial Covenant Protection</u></font><font style="font-size: 10pt;">. Moderna shall, until the
                    earlier of (i) the date on which the right of Genevant, Arbutus, or their respective designees to receive any contingent lump sum payment from Moderna has been fully and finally extinguished, and (ii) the date on which Moderna has paid
                    to Genevant, Arbutus, or their respective designees all contingent lump sum payments due under this Agreement, comply with the obligations in this Section 3.11. If, Moderna fails to maintain cumulative cash and cash equivalents,
                    investments (current and non-current) and outstanding liquidity related to undrawn loan facilities (determined in accordance with generally accepted accounting principles as reported in Moderna&#8217;s most recent quarterly or annual filing
                    with the SEC) of at least (x) at any time between the Effective Date and the date that any contingent payment is made by Moderna pursuant to Section 3.2, three billion United States Dollars (US $3,000,000,000.00), or (y) from the date
                    that any contingent payment is made by Moderna to Genevant, Arbutus, or their respective designees pursuant to Section 3.2, an amount equal to three billion United States Dollars (US </font>$3,000,000,000.00) <font style="font-family: 'Times New Roman'; font-style: italic;"><u>minus</u>&#160;</font>the amount of such contingent payment that was paid by Moderna to Genevant, Arbutus, or their respective designees, Moderna shall, within thirty (30) days after such failure
                  (the &#8220;Cure Period&#8221;), either secure its ability to satisfy the contingent lump sum payment under Section 3.2.1 by providing one or more of the following forms of financial assurance, in an aggregate amount not less than, in the case of
                  clause (x), one billion three hundred million United States Dollars (US $1,300,000,000.00), or in the case of clause (y), one billion three hundred million United States Dollars (US $1,300,000,000.00) <font style="font-family: 'Times New Roman'; font-style: italic;"><u>minus</u>&#160;</font>the amount of such contingent payment that was paid by Moderna to Genevant, Arbutus, or their respective designees:</div>
              </td>
            </tr>

        </table>
        <br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3d746cfa823641a4a411c9badc8ea126">

            <tr>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(a)</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">an irrevocable surety bond issued by a surety company rated at least "A-" by A.M. Best (or an equivalent rating by a nationally recognized rating agency);</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">18</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2b823fcc1b1b460785be121e55ee3b8d">

            <tr>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(b)</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">one or more irrevocable standby letters of credit issued by a United States lender having total assets of not less than [***];</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z85a72674d9a248ed903b22b4c0eccd42">

            <tr>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(c)</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">a cash escrow deposit held by an independent, nationally recognized escrow agent pursuant to an escrow agreement in form and substance reasonably acceptable to Genevant/Arbutus;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd6b95dcfc87e4ca084f3b031debf3487">

            <tr>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(d)</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">a segregated account over which Moderna shall grant Genevant/Arbutus a perfected, first-priority security interest, which shall be subject to customary restrictions reasonably acceptable to
                  Genevant/Arbutus; or</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55e25e3fd0f7456d9932b7c365d4b33b">

            <tr>
              <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(e)</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such other form of financial assurance as is reasonably acceptable to Genevant/Arbutus. Any financial assurance provided pursuant to this Section 3.11 shall name Genevant, Arbutus, and their
                  respective designees as beneficiaries and shall remain in effect until the earlier of (i) the date on which Moderna has paid all amounts payable or potentially payable by Moderna under this Agreement, or (ii) the date on which all of
                  Moderna&#8217;s obligations to make any such payments have been fully and finally extinguished. Moderna shall provide Genevant/Arbutus with (A) prompt written notice of the form of financial assurance selected and reasonable documentary
                  evidence thereof and (B) written notice [***] after becoming aware that Moderna&#8217;s cumulative cash and cash equivalents, investments (current and non-current), and outstanding liquidity related to undrawn loan facilities has fallen below
                  the threshold described in this Section 3.11.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">If Moderna fails to deliver the financial assurance pursuant to this Section 3.11 when due, Moderna shall deposit into an escrow account with an
          independent, nationally recognized escrow agent, to be released to Genevant, Arbutus or their respective designees when due in accordance with this Agreement, either (x) the full amount due under Section 3.2.1 (<font style="font-family: 'Times New Roman'; font-style: italic;">i.e.</font>, one billion three hundred million United States Dollars (US $1,300,000,000.00)), or (y) if any contingent payment was made by Moderna to Genevant, Arbutus, or their respective designees pursuant to
          Section 3.2, an amount equal to one billion three hundred million United States Dollars (US $1,300,000,000.00) <font style="font-family: 'Times New Roman'; font-style: italic;"><u>minus</u>&#160;</font>the amount of such contingent payment that was
          paid by Moderna. The escrow funds are to be released to Moderna upon delivery of financial assurance pursuant to this Section 3.11.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c83428ddbc84e4b87ed7e13da45671a">

            <tr>
              <td style="width: 18pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.12</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Tax Matters</u></font><font style="font-size: 10pt;">. Any payment made hereunder shall be net of applicable
                    withholding taxes, provided that:</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcadc1194d3da499c84f20665c51297bf">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.12.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Unless a relevant change in applicable law occurs between the date of this Agreement and the date of a particular payment to Genevant hereunder, [***].</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">19</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d549e9aece24461a57385a9c6a5dfb9">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.12.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Unless a relevant change in applicable law occurs between the date of this Agreement and the date of a particular payment to Arbutus hereunder, [***].</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb3ad53d0eebc4754a07e91bff66bd73a">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.12.3</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">If a withholding tax applies to a payment due under this Agreement, the Parties shall cooperate reasonably to complete any procedural formalities necessary to obtain any available relief,
                  reduction or exemption from such withholding. In addition, the paying party shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law. As soon as practicable after any
                  payment of such taxes to a governmental authority, the paying party shall deliver to the receiving party the original or a certified copy of a receipt issued by such governmental authority evidencing such payment, a copy of the return
                  reporting such payment or other evidence of such payment reasonably satisfactory to the receiving party.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf64cf9dfebf4438c9ae7b0fb283e1950">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.12.4</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">In the event that there is liability of Moderna or its Affiliates to pay, or of Genevant/Arbutus or their Affiliates to collect or remit, any sales, use, value-added, or similar taxes, or any
                  penalties or interest related thereto (collectively, &#8220;Sales Taxes&#8221;) in respect of license or other rights granted to Moderna or its Affiliates under this Agreement, Moderna shall be liable for and shall pay forthwith any such Sales Taxes
                  related thereto, and shall indemnify and hold Genevant/Arbutus and their Affiliates harmless in respect of such Sales Taxes.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4ce91db0ce234d90b807a4283fe52e5f">

            <tr>
              <td style="width: 18pt;">&#160;</td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.13</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Late Payments</u></font><font style="font-size: 10pt;">. Any late payments under this Agreement will accrue
                    interest at the rate of [***] per month, compounded quarterly, or the highest rate allowed by applicable law, whichever is less. [***]</font></div>
              </td>
            </tr>

        </table>
        <br>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="2780112754e341e8a357c2c3fb35df90" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"></td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.14</td>
              <td style="vertical-align: top; text-align: left;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Limitation of Patent Rights</u>. Moderna acknowledges and agrees
                      that, if any Genevant/Arbutus Patent Right is materially limited or declared invalid, unpatentable </font>or unenforceable, Moderna remains liable in full for any amounts payable under this Agreement but not yet paid and will not be
                    entitled to the return of any payments made.</font></font></td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">20</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z36591e77ceac48c1ab0500c193cebcb7">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>License to Moderna; Covenants</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcda80357ab2d4d89a712cba9ac777a80">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>License</u></font><font style="font-size: 10pt;">. Subject to the terms and conditions of this Agreement,
                    including Section 3.2, each of Genevant and Arbutus, on behalf of itself and its Affiliates, hereby grants to Moderna, and Moderna hereby accepts, a fully paid-up, royalty free, irrevocable, sublicensable (solely to Affiliates and Third
                    Party CMOs and CDMOs), nontransferable (except as expressly provided in Section 7.6), nonexclusive license, under the Genevant/Arbutus Patent Rights, to develop, have developed, make, have made, use, have used, distribute, have
                    distributed, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported, and otherwise dispose of Moderna Licensed Products anywhere in the world. This license fully exhausts all
                    Genevant/Arbutus Patent Rights as to Moderna Licensed Products and the practice of any method or process in connection with Moderna Licensed Products. For clarity, each Genevant/Arbutus Patent Right (regardless of jurisdiction) shall be
                    deemed exhausted by any sale, provision, or disposition of Moderna Licensed Products, regardless of the jurisdiction in which such Moderna Licensed Products were made or first sold, to the same extent that such Genevant/Arbutus Patent
                    Right would have been exhausted if such Moderna Licensed Products were made and first sold in the jurisdiction in which such Genevant/Arbutus Patent Right was issued.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0cc7932c3030464aa8baf95fb1ad0f5f">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Change of Control</u></font><font style="font-size: 10pt;">. In the event of a Change of Control of a Moderna
                    Party, the licenses, releases and other rights granted to such Moderna Party under this Agreement shall remain in effect solely with respect to the Moderna Licensed Products of such Moderna Party that were in clinical development,
                    clinically developed or commercialized by such Moderna Party or its Affiliates immediately prior to the closing of such Change of Control, and natural evolutions of such Moderna Licensed Products. The term natural evolutions includes
                    updated versions of such products to address new viral strains or variants. Without limiting the foregoing, the licenses, releases and other rights granted to such Moderna Party under this Agreement shall not extend to or cover any
                    products, platforms, programs or other assets of any Third Party acquirer in such Moderna Change of Control or any Affiliates of such Third Party acquirer (other than such Moderna Party and its existing Affiliates). For the avoidance of
                    doubt, no products, platforms, programs or other assets of a Third Party shall become Moderna Licensed Products of such Moderna Party by virtue of being combined, co-formulated, co-developed, manufactured, or commercialized with a
                    Moderna Licensed Product following a Change of Control of such Moderna Party.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">21</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f75efb094ea48b48edf579fc918010c">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Covenants to Moderna</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z05375762a2a249a1bd5a2554b95dfe91">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.3.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each of Genevant, Genevant Parent, and Arbutus, on behalf of itself and its Affiliates, covenants and agrees that it and each of its Affiliates will not assert any claim for direct or indirect
                  (including induced or contributory) infringement against Moderna or its Affiliates at any time, under any Genevant/Arbutus Patent Right anywhere in the world based on any manufacture, use, selling, offering to sell, distributing,
                  importing, exporting and otherwise transferring or disposing of Moderna Licensed Products, past, present or future, or the practice of any process or method of operation for any such products.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0b7dc3991b5419e8283bc5b08b110d5">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.3.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each of Genevant, Genevant Parent, and Arbutus, on behalf of itself and its Affiliates, covenants and agrees that it and each of its Affiliates will not assert any claim for direct or indirect
                  (including induced or contributory) infringement against Moderna or its Affiliates at any time, under any Specified Patent or EPO Patent Right anywhere in the world based on any manufacture, use, selling, offering to sell, distributing,
                  importing, exporting and otherwise transferring or disposing of any product (a) that is not a Moderna Licensed Product and (b) that is or will be (i) licensed or authorized according to a Regulatory Application filed by Moderna, (ii) sold
                  by or on behalf of Moderna or its applicable Affiliate as its own product, or (iii) developed by Moderna, past, present or future, or the practice of any process or method of operation for any such products.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z38e25ed825cf44148f522da2c537c510">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.3.3</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each of Genevant, Genevant Parent, and Arbutus, on behalf of itself and its Affiliates, covenants and agrees that they will not cite, reference, rely upon, or introduce into evidence the Consent
                  Judgment and Order (Exhibit 2.3) entered in the US Litigation (including any stipulated findings of infringement or invalidity contained therein), or any portion thereof, in any court, tribunal, arbitration, administrative proceeding, or
                  other forum anywhere in the world, at any time, for any purpose against Moderna or any of its Affiliates.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zac772ab0cda44b268f17d94a2ae8a87c">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Covenant to Related Third Parties</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf267517489eb4407b1a05303af8b3fcd">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.4.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each of Genevant, Genevant Parent, and Arbutus, on behalf of itself and its Affiliates, covenants and agrees that it and each of its Affiliates will not assert any claim for direct or indirect
                  (including induced or contributory) infringement against any Moderna or Moderna Affiliate customers, suppliers, manufacturers, service providers, licensees and third parties in Moderna&#8217;s or a Moderna Affiliate&#8217;s development,
                  commercialization or distribution chain or with whom Moderna has entered into a collaboration agreement or license agreement (all of whom the Parties agree to be intended third-party beneficiaries of this Agreement, and collectively,
                  &#8220;Related Third Parties&#8221;) at any time under any Genevant/Arbutus Patent Right anywhere in the world, in each case based on their development, manufacture, use, selling, offering to sell, distributing, importing, exporting and otherwise
                  transferring or disposing of Moderna Licensed Products, past, present or future, or their practice of any process or method of operation for any such Moderna Licensed Product.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">22</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7f3f9c7b77c43b6a89114644f531e88">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.4.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each of Genevant, Genevant Parent, and Arbutus, on behalf of itself and its Affiliates, covenants and agrees that it and each of its Affiliates will not assert any claim for direct or indirect
                  (including induced or contributory) infringement against any Related Third Parties at any time under any Specified Patent or EPO Patent Right anywhere in the world, in each case based on their development, manufacture, use, selling,
                  offering to sell, distributing, importing, exporting and otherwise transferring or disposing of any product that (a) is not a Moderna Licensed Product and (b) that is or will be (i) licensed or authorized according to a Regulatory
                  Application filed by Moderna or its licensee, (ii) sold by or on behalf of Moderna or its applicable Affiliate or licensee as its own product, or (iii) developed by Moderna, past, present or future, or the practice of any process or
                  method of operation for any such products.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6e8b74d558284f209d5feaeefd8fbdbf">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.5</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Implied Rights</u></font><font style="font-size: 10pt;">. No rights shall arise, and nothing in this
                    Agreement shall be construed as the grant by either Party, by implication, estoppel, exhaustion, integration, or otherwise, of any intellectual property rights other than as expressly set forth in this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z822b798eb4894f52919447945037a2d9">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5.</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt; width: auto;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>Warranties and Representations</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfcd3e49c3f514f509dfb7e904ad8c2d7">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mutual Representations</u></font><font style="font-size: 10pt;">. Each of Genevant and Arbutus, on the one hand,
                    and Moderna, on the other hand, represents and warrants to the other(s), as of the Effective Date, that:</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb43881d59f284a45b3eab8e61f4415fd">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement
                  and to carry out the provisions hereof;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93bb56a9859641ed90a54b9b718fe631">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such Party has taken all corporate action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8c3dd408d792494d827121ec60854d10">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.3</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">this Agreement has been duly executed by such Party and constitutes a valid and legally binding obligation of such Party, enforceable in accordance with its terms;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd85dc1a7db78415a91fc5763c6e08b44">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.4</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it
                  may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it;</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0eca8ea9297d44a49648d70954f62720">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.5</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such Party has the right to grant the licenses and releases granted hereunder, and has the right to settle the US Litigation and Ex-US Litigation;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdb21643f3c2645d0a94b3703db01de33">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.6</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such Party has been advised by its counsel of its rights and obligations under this Agreement and enters into this Agreement freely, voluntarily, and without duress;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7df24d0dd8b477fa291334230b68a42">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.7</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such Party is not relying on any promises, inducements, or representations other than those provided herein;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">23</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zed723fbd9e12440e94c760c8aef3a321">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.8</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">there is no lawsuit or any other civil or administrative proceeding, or any claim or counterclaim of any kind, in any court, tribunal, government entity or agency, or dispute resolution
                  proceeding (including arbitration and mediation) pending on the Effective Date that was commenced by or on behalf of such Party or any of its Affiliates against any other Party or any of its Affiliates other than the US Litigation and the
                  Ex-US Litigation; and</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z67508b0d6344458a8f4020456eadd606">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.1.9</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">such Party has not transferred, assigned, subrogated or pledged to any Third Party or to an Affiliate, the right to bring, pursue, or settle any of the claims, counterclaims, or demands released
                  pursuant to Section 2 of this Agreement.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18c7327bfabd49e18ca72da77634b8ae">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.2</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Genevant/Arbutus Representations</u></font><font style="font-size: 10pt;">. Each of Genevant, Genevant Parent
                    and Arbutus represents and warrants to Moderna, as of the Effective Date, that: (i) in the twelve </font>(12) months prior to and including the Effective Date, neither it nor any of its Affiliates has exclusively licensed (in part or
                  whole), transferred or assigned or purported to transfer or assign to any Person any Patent that if owned or controlled by Genevant, Arbutus, or any of their Affiliates as of the Effective Date, would be a Genevant/Arbutus Patent Right;
                  (ii) neither it nor any of its Affiliates have participated in any way (directly or indirectly) in any transaction the purpose or effect of which is to avoid or prevent Moderna or any Related Third Parties from receiving or enjoying any
                  part of the benefit of any of the rights, licenses, covenants, or releases provided for in this Agreement, and (iii) it has the full right and authority to enter into this Agreement on behalf of and bind all of its Affiliates, and
                  covenants that it shall cause all such Affiliates to comply with, and grant all necessary rights, licenses, covenants, and releases to effect, this Agreement, and all other terms and conditions of this Agreement, and shall be directly
                  liable to Moderna and its Affiliates for any breach of this Agreement by any Affiliates of Genevant or Arbutus, including any failure by any such Affiliate to grant any such right, license, covenant, or release. Each of Genevant, Genevant
                  Parent, and Arbutus shall defend, indemnify and hold harmless Moderna and its Affiliates, and their Related Third Parties for any and all costs and expenses (including reasonable fees of attorneys and other professionals), liabilities,
                  damages, and losses arising out of or resulting from breach of this Section 5.2, including from any actual or threatened assertion of any Patent that would have been a Genevant/Arbutus Patent Right if the representations and warranties in
                  this Section 5.2 were true. Genevant Parent further represents and warrants to Moderna that as of the Effective Date, it does not directly own or directly control the Genevant/Arbutus Patent Rights or the EPO Patent Rights.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9eb38e4869f045f3badd05871ae1b4a8">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 28.8pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.3</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Other Warranties</u></font><font style="font-size: 10pt;">. Except for the express warranties and
                    representations set forth in Section 5.1 and Section 5.2, none of the Parties makes any warranties or representations, express or implied, either in fact or by operation of law, by statute or otherwise, and each Party disclaims all
                    other warranties and representations, including any implied warranty of fitness for a particular purpose, validity or non-infringement.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e9478b399d0404193cae1312faa14b6">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">6.</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt; width: auto;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>Confidentiality</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze6b1592bf3f4474eb70da0015b2cbc15">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Limitations on Disclosure</u></font><font style="font-size: 10pt;">. The Parties shall not, and shall cause
                    their Affiliates and their respective employees, officers, directors and other representatives (including accountants, attorneys and auditors) not to, disclose the terms of this Agreement to any Third Party, except as provided in
                    Sections 6.1.1 through 6.1.5.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">24</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze6ec5bf1040d4d388256e72d247680b9">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.1.1</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">The terms of this Agreement may be disclosed, without notice to the other Parties, to (i) any Party&#8217;s and its Affiliates&#8217; legal counselors, auditors, accounting, financial advisors, or other
                  similar professionals representing a Party, so long as any such Persons are bound by confidentiality obligations that extend to the terms of this Agreement; and (ii) any Third Party that is a bona fide actual or potential investor,
                  acquirer, merger partner, or other financial partner of a Party or an Affiliate for the purpose of evaluating an investment, acquisition, merger, or similar transaction, so long as any such Third Party agrees to be bound by
                  confidentiality requirements at least as strict as those set forth in this Agreement.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8cb56f94aaa14257ac892b7b13a77c2f">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.1.2</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">A Party or its Affiliate may disclose the existence and terms of this Agreement (i) as required by any applicable law, regulation, court order, legal process, stock exchange rule, or governmental
                  authority, including the Securities Act of 1933, the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder, or (ii) in connection with any filing required to be made with the U.S. Securities and Exchange
                  Commission (&#8220;SEC&#8221;) or other applicable securities regulator. If a Party or its Affiliate determines, upon advice of counsel (internal counsel being sufficient), that it is required to file this Agreement or a description hereof with the
                  SEC or other securities authority (including as an exhibit to a periodic report or current report), such Party or its Affiliate may do so. To the extent reasonably practicable and permitted by law, the filing Party or its Affiliate shall
                  provide the other Party with a reasonable opportunity to review and comment on any proposed filing that describes this Agreement, and shall consider in good faith any reasonable requests for redaction of confidential information
                  consistent with applicable securities laws and SEC rules.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z60a8dfe041b24cd0b4eade963d9f8970">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.1.3</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Any Party may issue press releases or make public announcements regarding this Agreement that consist only of (i) the amount and conditions of the payments to be made by Moderna hereunder,
                  including the protective provisions associated therewith, (ii) any judgment or order entered into by any court related to the US Litigation or Ex-US Litigation, (iii) the general structure of the Agreement (e.g., the fact that it includes
                  a license, releases, etc.) and (iv) content that is not a term of this Agreement. Such announcements and press releases may only be made on or after 4:15 p.m. New York time on March 3, 2026.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z33200caf64dc42ff94507888f5bb2fc6">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.1.4</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">If a Party or an Affiliate is required to provide the terms of this Agreement to a Third Party pursuant to a discovery demand, discovery order, or other legal processes or requirements, including
                  as necessary purposes of enforcing the terms of this Agreement, it shall inform the other Parties in sufficient time prior to any such disclosure to allow the other Parties to seek a protective order or confidential treatment prior to any
                  such disclosure.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z378b8083f3e74ed984134cfeee320d1e">

            <tr>
              <td style="width: 45pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.1.5</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">The terms of this Agreement may be disclosed as otherwise agreed to by the Parties in writing.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">25</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01c55201682c4752b3a63e36d9076962">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">7.</td>
              <td style="vertical-align: top; text-align: left; font-size: 10pt; width: auto;">
                <div style="font-family: 'Times New Roman'; font-weight: bold;"><u>General Provisions</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1ce31659a5274993935030258a41ccbb">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.1</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Settlement</u></font><font style="font-size: 10pt;">: Without limitation of the consent judgment in the US
                    Litigation, <font style="font-family: 'Times New Roman'; color: rgb(34, 34, 34);">this Agreement, including the Contingent and Non-Contingent Payments, evidences a compromise and settlement of disputed claims and nothing in this
                      Agreement, or the fact of the Parties&#8217; respective execution of it, may be deemed or construed to be an admission of fault of any kind, which fault is expressly denied.</font></font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6da562c23cb248aa9b440fc6c2f404ad">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.2</td>
              <td style="vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Term of License</u></font><font style="font-size: 10pt;">. The licenses granted under this Agreement shall
                    commence upon the Effective Date and shall continue until the expiration of the last-to-expire Patent that is or becomes a Genevant/Arbutus Patent Right.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8fb7f2cbb989480fbc6fcd0ab10214f5">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.3</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Choice of Law and Venue</u></font><font style="font-size: 10pt;">. This Agreement shall be governed and
                    interpreted in accordance with the laws of the State of Delaware without regard to conflicts of law principles. The federal and state courts of Delaware shall have exclusive jurisdiction (to the extent that they have subject matter
                    jurisdiction) in all matters arising under this Agreement, and the Parties hereto expressly consent and submit to the personal jurisdiction and venue of such courts for the limited purpose of enforcing the terms of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0759d7e3cf38485ba48afbe4b3246402">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.4</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Stipulated Remedies for Certain Material Breaches</u></font><font style="font-size: 10pt;">. Each Party
                    acknowledges and agrees that the restrictions and other terms and conditions set forth herein are reasonable and necessary to protect the respective legitimate interests of the Parties. The Parties also agree that irreparable damage,
                    for which monetary damages (even if available) would not be an adequate remedy, would occur in the event of a breach of Section 2.4 or Section 2.5. Accordingly, the Parties acknowledge and agree that each of Genevant and Arbutus shall
                    be entitled to an injunction, specific performance and other equitable relief to prevent a breach or threatened breach of Section 2.4 or Section </font>2.5 and to enforce specifically the terms and provisions thereof, in addition to
                  any other remedy to which they are entitled in law or in equity. Moderna agrees that it will not oppose the granting of such injunction, specific performance and other equitable relief on the basis that Genevant/Arbutus has an adequate
                  remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. If either Genevant or Arbutus seeks an injunction or injunctions to prevent a breach or threatened breach of Section
                  2.4 or Section 2.5 and to enforce specifically such section, it shall not be required to provide any bond or other security in connection with such order or injunction.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f653a86e09d49d7881b43af38223973">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 28.8pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.5</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Waiver</u></font><font style="font-size: 10pt;">. A waiver by any Party of any of the terms and conditions of
                    this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in
                    this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of any Party.</font></div>
              </td>
            </tr>

        </table>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">26</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z70b7adb574e44896804b069a892639ee">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.6</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Bankruptcy</u></font><font style="font-size: 10pt;">. All rights and licenses granted under or pursuant to any
                    Section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;), licenses of &#8220;intellectual property&#8221; as defined under the Bankruptcy Code. The
                    Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17a0d00c2a9240efb7663024e8b2079e">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.7</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Assignment</u></font><font style="font-size: 10pt;">. This Agreement and the rights herein shall not be
                    assignable or otherwise transferable without the written consent of the Parties except as provided in this Section 7.7. The prior written consent of the Parties shall not be required (i) for a Party to assign or transfer this Agreement
                    in its entirety pursuant to a sale of all or substantially all of the assets of the entity or business division to which this Agreement relates, whether pursuant to a merger, consolidation, or similar transaction involving such Party,
                    or (ii) for a Party to assign or transfer this Agreement in its entirety to an Affiliate; provided, however, that Moderna will in any event remain responsible for the payments to Genevant, Arbutus, or their respective designees required
                    by Section 3 to the extent that an assignee of Moderna fails to make any such payment when due. The Agreement, as well as the rights and obligations herein, shall be binding upon and inure to the benefit of the Parties and their
                    respective successors and assigns as if such successors and assigns were the original Parties to this Agreement or the respective rights and obligations. For avoidance of any doubt, any successors or assigns to this Agreement are
                    permitted to assign the Agreement as if they were the original Parties to it, subject to the conditions of this Section 7.7. Any purported assignment or transfer in violation of this Section shall be null and void <font style="font-family: 'Times New Roman'; font-style: italic;">ab initio</font>.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcd280c0088c84d9ca70ed57dc395208d">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.8</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Assignment of Genevant/Arbutus Patent Rights</u></font><font style="font-size: 10pt;">. Genevant/Arbutus agrees,
                    each on behalf of itself and each of its Affiliates, that all of the licenses, releases, covenants, and other rights granted by them and all their obligations set forth in this Agreement (the &#8220;Patent Obligations&#8221;) shall run with the
                    Genevant/Arbutus Patent Rights, and that Genevant/Arbutus shall ensure that any assignee, transferee, or successor to any of the Genevant/Arbutus Patent Rights (including the acquiring or surviving entity in connection with any
                    acquisition or other change of control of Genevant/Arbutus), or any other Person (such as an exclusive licensee) that obtains any enforcement rights with respect to any of the Genevant/Arbutus Patent Rights agrees in writing, prior to
                    such assignment, transfer or grant, to be bound by the relevant Patent Obligations (including the obligation to obtain such written agreement from any subsequent assignee, transferee, successor or grantee). Genevant/Arbutus shall
                    indemnify and hold harmless Moderna and its Affiliates, and the Related Third Parties for any costs and expenses (including reasonable fees of attorneys and other professionals), liabilities, damages and losses arising out of or
                    resulting from any breach of this Section 7.8 by Genevant/Arbutus or their Affiliates, including from any assertion of any Genevant/Arbutus Patent Rights that would have been prevented by compliance with this Section 7.8.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf63e7214b6624648a4554b2d0fd4bd7f">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.9</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Costs</u></font><font style="font-size: 10pt;">. Each Party shall each bear its own costs and legal fees
                    associated with the Litigation and with the negotiation and preparation of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">27</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf5f5a9b8cef64d8eb00673d3429d26ff">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.10</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability</u></font><font style="font-size: 10pt;">. When possible, each provision of this Agreement will be
                    interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of
                    such prohibition or invalidity, without invalidating the remainder of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za78e16edb9cc46fc94e9963f7c77e141">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.11</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Integration</u></font><font style="font-size: 10pt;">. The Agreement and its Exhibits constitute the entire
                    agreement between the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings, both oral and written, between the Parties with respect to such subject matter. No Party is relying on any
                    promises, representations, conditions, provisions, or terms other than those set forth in this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z87a490f564254729b1e0453f88a8daf0">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.12</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Amendments</u></font><font style="font-size: 10pt;">. No amendment, modification or supplement of any provisions
                    of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96198772cdbd4f23b20d9c89f16d8e8d">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.13</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Headings</u></font><font style="font-size: 10pt;">. The captions and descriptive headings of this Agreement are
                    for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00d43577f93e49adbc691f1faaeab54d">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.14</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Waiver of Rule of Construction</u></font><font style="font-size: 10pt;">. Each Party has had the opportunity to
                    consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zce6c81b07ace4cf7a6770d3fd9445298">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.15</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Third Party Beneficiaries</u></font><font style="font-size: 10pt;">. Except as expressly provided herein,
                    nothing in this Agreement, either express or implied, is intended to or shall confer upon any Third Party any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e2370dbcdf24542b7310994507bc2a9">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.16</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notices</u></font><font style="font-size: 10pt;">. Notices required or permitted under this Agreement shall be
                    in writing and sent by prepaid registered or certified air mail or by overnight express mail (e.g., FedEx) or by email (provided that no &#8220;bounce-back&#8221; or similar notice of non-delivery is received), and shall be deemed to have been
                    properly served to the addressee upon receipt of such written communication to the following addresses of the Parties:</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; margin-left: 108pt;">If to Moderna:</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">325 Binney Street,</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Cambridge, MA 02142</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Attention: Shannon Thyme Klinger [***]</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">With a copy to:</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Jeanna Wacker, Kirkland </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">&amp; Ellis LLP, 601 Lexington Avenue,</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">New York, NY 10022</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">[***]</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">28</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; margin-left: 108pt;">If to Genevant:</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Viaduktstrasse 8,</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">4051 Basel Switzerland</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Attention: [***]</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Attention: [***]</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">With a copy to:</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">David Berl [***]</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Williams &amp; Connolly LLP 680 </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Maine Avenue SW Washington, </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">D.C. 20024</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; margin-left: 108pt;">If to Arbutus:</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">700 West Georgia St. 25th Floor</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Vancouver, British Columbia V7Y1B3 Canada</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Attention: [***]</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">With a copy to:</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Adam Brausa [***]</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">Morrison &amp; Foerster LLP</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">425 Market Street</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-left: 108pt;">San Francisco, California 94105</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9fb394c76c5a4605b3df6e777dd20664">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.17</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Counterparts</u></font><font style="font-size: 10pt;">. This Agreement may be executed in any number of
                    signature page counterparts transmitted via facsimile or electronic mail, any one of which need not contain the signature of more than one Party but all such counterparts taken together shall constitute one and the same Agreement.</font></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc6e87507891e4d5c95664ae6343a6cb8">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.18</td>
              <td style="vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Interpretation</u></font><font style="font-size: 10pt;">. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall
                    be deemed to be followed by the phrase &#8220;without limitation.&#8221; The words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. All
                    references herein to Articles, Sections, and Exhibits shall be deemed references to Articles and Sections of, and Exhibits to, this Agreement unless the context shall otherwise require. Except where the context otherwise requires,
                    wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and/or). Whenever this Agreement refers to a
                    number of days, unless otherwise specified, such number refers to calendar days.</font></div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; text-indent: 36pt; margin-right: 46.4pt; margin-left: 71.95pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, each of the Parties has approved and executed this Agreement by and through its duly
          authorized officer or agent.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE PAGE FOLLOWS]</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">29</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
          </div>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the Effective Date.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="font-size: 10pt;">
          <table cellspacing="0" cellpadding="0" border="0" id="zb63ff53d5aa442988c8f9c2d1437b47d" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 50.00%;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Genevant Sciences GmbH</font></td>
                <td style="width: 50.00%;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;">Moderna, Inc.</font></font></td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><br>
                </td>
                <td style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><font style="font-size: 10pt; font-family: 'Times New Roman';">By: [***]</font></td>
                <td style="width: 50.00%;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">By: [***]</font></font></td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><br>
                </td>
                <td style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">Name: [***]</td>
                <td style="width: 50.00%;">Name: [***]</td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><br>
                </td>
                <td style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">Title: [***]</td>
                <td style="width: 50.00%;">Title: [***]</td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><br>
                </td>
                <td style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Arbutus Biopharma Corp.</font></td>
                <td style="width: 50.00%;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;">ModernaTX, Inc.</font></font></td>
              </tr>
              <tr>
                <td style="width: 50.00%;"><br>
                </td>
                <td style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;"><font style="font-size: 10pt; font-family: 'Times New Roman';">By: [***]</font></td>
                <td rowspan="1" style="width: 50.00%;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">By: [***]</font></font></td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;">Name: [***]</td>
                <td rowspan="1" style="width: 50.00%;">Name: [***]</td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;">Title: [***]</td>
                <td rowspan="1" style="width: 50.00%;">Title: [***]</td>
              </tr>

          </table>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;">
              <div style="font-size: 10pt;">
                <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                    <tr>
                      <td colspan="3">
                        <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                          AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                      </td>
                    </tr>
                    <tr>
                      <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                      <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                      <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 33%; text-align: left;">
                        <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                      </td>
                      <td style="width: 34%; text-align: center; font-size: 8pt;">30</td>
                      <td style="width: 33%; text-align: center;">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION COPY</div>
            </div>
          </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td rowspan="1" style="width: 50%; font-style: italic; font-weight: bold;">Solely for purposes of the Genevant Parent Provisions</td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50%; font-weight: bold;">Genevant Sciences Ltd.</td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;">By: [***]</td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;">Name: [***]</td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;">&#160;</td>
                <td rowspan="1" style="width: 50.00%;">&#160;</td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 50.00%;">Title: [***]</td>
                <td rowspan="1" style="width: 50.00%;"><br>
                </td>
              </tr>

          </table>
        </div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="font-size: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;">
            <div style="font-size: 10pt;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td colspan="3">
                      <div style="text-align: center; margin-left: 1pt; font-family: 'Times New Roman'; font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL
                        AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 33%; text-align: left;">&#160;</td>
                    <td rowspan="1" style="width: 34%; text-align: center;">&#160;</td>
                    <td rowspan="1" style="width: 33%; text-align: center;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 33%; text-align: left;">
                      <div style="text-align: left; margin-left: 1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt;">SETTLEMENT AGREEMENT</div>
                    </td>
                    <td style="width: 34%; text-align: center; font-size: 8pt;">31</td>
                    <td style="width: 33%; text-align: center;">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>roiv-20260303.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<xs:schema targetNamespace="http://roivant.com/20260303" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:roiv="http://roivant.com/20260303" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20260303_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20260303_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://roivant.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>roiv-20260303_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>roiv-20260303_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://roivant.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="roiv-20260303.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 03, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  03,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Roivant Sciences Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1173944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">50 Broadway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SW1H 0DB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-3347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, $0.0000000341740141 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ROIV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20068452_8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" isOnlyDei="true" isUsgaap="true" original="ef20068452_8ka.htm">ef20068452_8ka.htm</File>
    <File>roiv-20260303.xsd</File>
    <File>roiv-20260303_lab.xml</File>
    <File>roiv-20260303_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20068452_8ka.htm": {
   "nsprefix": "roiv",
   "nsuri": "http://roivant.com/20260303",
   "dts": {
    "inline": {
     "local": [
      "ef20068452_8ka.htm"
     ]
    },
    "schema": {
     "local": [
      "roiv-20260303.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "roiv-20260303_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "roiv-20260303_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://roivant.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20260303to20260303",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20068452_8ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260303to20260303",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20068452_8ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001140361-26-010656-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-26-010656-xbrl.zip
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M<2A%(%!RB>Q@'Q7=(%,J#+HF2O$-1A)'0>;J5/UW;S*^51:C 'N]E87C-!)
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MKQ/3MO,1>1<EB7QFUO)JSVX58HQFL)_W0<);W+7[-O5<AUDT"!P:&&9@!/W
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M^/VO;SZ].3MO=F1^G95":34KEPK3&C[^[?3\%!:RPI/B?5Z>@N+3'?COTE_
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MR*N$W17)\KN(88G0:Z?5D#9Z]$TJK1'A'(OK\>R"B5[I%SCRF$:>M2,G]4'
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MO7V?:]\_SO=XE/K28CQV/,YLSS;<@,6Q'5B68_%E:/']*?5##MJ[3_><^"1
MLO?HI=@Y+D;[JX&^NF(AF9P$QH4U0C+SR?;< JXKT#@2=545"7':(]:(3@_9
MO'T#240XGE(+>"S*2#9^W>3PTF1%U?6J%[OX(2GH,;R3&%0Y/J93[4,FKQBC
M:D&D<XA_<:Q1P>^O8#=$274S0<G+,QA^R%F0I'@1+IO(9)9AOA:=YN!<W#CO
M/@H^%^K,)[#;$E5'9\/E38D[$T:\6N=EHA!IP_P\#+/Q/ @CKA[9HU2GX92G
MVE_S:WR?U"%W;-F&6=Z1ML#C2S"<W+^7\IGT_L<0?' 9F )<] W$O/#6I+"X
MSRCB3[B&L,##E'#?R0NZ)P]LB[A&-AY)IH,$-0IWWN]3,+RI;"T\83V,]V-N
MK*@)Q&)K(/5V0,$)( ^O,104K&.3SSC:2*R@_#M8./"LI+R<6"D<"NU1,*U
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MW63/^UQ[M\+X;-3A%MZUKAY^+(N116$K*Q)4R52A#2I4G#D4G1QW&X:5R:
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MB">W<28"BVS9KPFU8$H/BUV85T6OB6=1'Z9]K'=7>E'@G@9L31Y85MO(/JM
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M[Z[IL'XYH?!#=Q]:0$=8!MU6GE]C.< 4E!@B2.LQ)8+!-2\*UH'$NBH0T+J
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MQOR:KV5$^G\;_]I=^G1D]?)?_^4__R-M\A7^XW8QK\0__A]02P,$%     @
MA$5W7*^V^6)$ P  -@\  !$   !R;VEV+3(P,C8P,S S+GAS9+5776_3,!1]
M1^(_F+P['\TZT6K=!-J&)@V&!DB\(==Q6HO$#K:SMO\>VXG3]'-- V^.[SWG
M'E_?Z]Y>W2SS#+P0(2EG$R_R0P\0AGE"V6SBE1(BB2GU;J[?OKEZ!^$GPHA
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MC<@7^2?MC_\#4$L! A0#%     @ A$5W7 ]8^JEX%0  U7T  !(
M     ( !     &5F,C P-C@T-3)?.&MA+FAT;5!+ 0(4 Q0    ( (1%=URQ
M0P_5YX8  "AF!  5              "  :@5  !E9C(P,#8X-#4R7V5X,3 M
M,2YH=&U02P$"% ,4    " "$17=<K[;Y8D0#   V#P  $0
M@ '"G   <F]I=BTR,#(V,#,P,RYX<V102P$"% ,4    " "$17=<MT;S3'H(
M   P5@  %0              @ $UH   <F]I=BTR,#(V,#,P,U]L86(N>&UL
M4$L! A0#%     @ A$5W7!XJ#@O;!0  [SX  !4              ( !XJ@
L ')O:78M,C R-C S,#-?<')E+GAM;%!+!08     !0 % $@!  #PK@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>ef20068452_8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="roiv-20260303.xsd" xlink:type="simple"/>
    <context id="c20260303to20260303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2026-03-03</startDate>
            <endDate>2026-03-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20260303to20260303"
      id="Fact_173987dffc66412481442c35adce3f05">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20260303to20260303"
      id="Fact_2733d47eee5b40e6a5d26e9ec617c72a">0001635088</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20260303to20260303"
      id="Fact_03b10c1b292e4aaf817a01cc3f244a02">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20260303to20260303"
      id="Fact_c8c6affcacf0487eb5bae78d3d2a174a">2026-03-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20260303to20260303"
      id="Fact_13281207eecf4bb4be3e33b81dbeccc3">Roivant Sciences Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20260303to20260303"
      id="Fact_112a74d77838425eaf6c5e05f757e37e">D0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20260303to20260303"
      id="Fact_dfe7f17ac7e04eee8dcf2a65e9b5fa1c">001-40782</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20260303to20260303"
      id="Fact_03969f308e00462e8da781db3a32ddf2">98-1173944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20260303to20260303"
      id="Fact_8c77e1c9cea84d51a8d5a0bafda0157a">7th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20260303to20260303"
      id="Fact_2d608e5d97674b98a54ff84f23f2f6fb">50 Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20260303to20260303"
      id="Fact_1466c9deaad6444a89bebbc1c845db43">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="c20260303to20260303"
      id="Fact_574ebeb9cddd44abbd96d2cb37f1371d">SW1H 0DB</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="c20260303to20260303"
      id="Fact_bfd51f3709874c558d3b1613721b6fd0">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="c20260303to20260303"
      id="Fact_703642680bfb416bb00aa0c4749e8594">207</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20260303to20260303"
      id="Fact_5a2cfd84016b4311b81f1441825eec76">400-3347</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20260303to20260303"
      id="Fact_241596e971354a9498aad548257e68be">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20260303to20260303"
      id="Fact_f5200c264f454868a9163d759958a4ad">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20260303to20260303"
      id="Fact_9ed51f7afc48491888811bf947ffb594">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20260303to20260303"
      id="Fact_36be14c54212463c9ec777bfc9347ca2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20260303to20260303"
      id="Fact_6613dfebb7bc4f97a63ff9b02429b499">Common Shares, $0.0000000341740141 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20260303to20260303"
      id="Fact_6644577ba67f4126a2b617b5b2df97c6">ROIV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20260303to20260303"
      id="Fact_14fe63333af0418f8e026a013374c4ef">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20260303to20260303"
      id="Fact_dfef9264f98540829d0d8fe301690404">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
